Method for modulating gpr119 g protein-coupled receptor and selected compounds

ABSTRACT

A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.

RELATED APPLICATION

This application is a divisional of U.S. patent application Ser. No.13/041,564, filed Mar. 7, 2011, now allowed, which claims prioritybenefit of U.S. patent application Ser. No. 12/173,864, filed Jul. 16,2008, issued as U.S. Pat. No. 7,928,230 B2, which claims prioritybenefit of U.S. Provisional Application 60/950,162, filed on Jul. 17,2007. The entirety of each of these applications is incorporated hereinby reference.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a serious disease afflicting over 100 millionpeople worldwide. In the United States, there are more than 12 milliondiabetics, with 600,000 new cases diagnosed each year. Diabetes mellitusis a diagnostic term for a group of disorders characterized by abnormalglucose homeostasis resulting in elevated blood sugar. There are manytypes of diabetes, but the two most common are Type 1 (also referred toas insulin-dependent diabetes mellitus or IDDM) and Type 2 (alsoreferred to as non-insulin-dependent diabetes mellitus or NIDDM).

The etiology of the different types of diabetes is not the same;however, everyone with diabetes has two things in common: overproductionof glucose by the liver and little or no ability to move glucose out ofthe blood into the cells where it becomes the body's primary fuel.

People who do not have diabetes rely on insulin, a hormone made in thepancreas, to move glucose from the blood into the cells of the body.However, people who have diabetes either do not produce insulin orcannot efficiently use the insulin they produce; therefore, they cannotmove glucose into their cells. Glucose accumulates in the blood creatinga condition called hyperglycemia, and over time, can cause serioushealth problems.

Diabetes is a syndrome with interrelated metabolic, vascular, andneuropathic components. The metabolic syndrome, generally characterizedby hyperglycemia, comprises alterations in carbohydrate, fat and proteinmetabolism caused by absent or markedly reduced insulin secretion and/orineffective insulin action. The vascular syndrome consists ofabnormalities in the blood vessels leading to cardiovascular, retinaland renal complications. Abnormalities in the peripheral and autonomicnervous systems are also part of the diabetic syndrome.

Diabetes has also been implicated in the development of kidney disease,eye diseases and nervous-system problems. Kidney disease, also callednephropathy, occurs when the kidney's “filter mechanism” is damaged andprotein leaks into urine in excessive amounts and eventually the kidneyfails. Diabetes is also a leading cause of damage to the retina at theback of the eye and increases risk of cataracts and glaucoma. Finally,diabetes is associated with nerve damage, especially in the legs andfeet, which interferes with the ability to sense pain and contributes toserious infections. Taken together, diabetes complications are one ofthe nation's leading causes of death.

Many people with NIDDM have sedentary lifestyles and are obese; theyweigh approximately 20% more than the recommended weight for theirheight and build. Furthermore, obesity is characterized byhyperinsulinemia and insulin resistance, a feature shared with NIDDM,hypertension and atherosclerosis.

Obesity, which is the result of an imbalance between caloric intake andenergy expenditure, is highly correlated with insulin resistance anddiabetes in experimental animals and human. However, the molecularmechanisms that are involved in obesity-diabetes syndromes are notclear. During early development of obesity, increased insulin secretionbalances insulin resistance and protects patients from hyperglycemia (LeStunff et al., Diabetes, 43:696-702 (1989)). However, over time, β-cellfunction deteriorates and non-insulin-dependent diabetes develops inabout 20% of the obese population (Pederson, P., Diab. Metab. Rev.,5:505-509 (1989)) and (Brancati, F. L. et al., Arch. Intern. Med.,159:957-963 (1999)). Given its high prevalence in modern societies,obesity has thus become the leading risk factor for NIDDM (Hill, J. O.et al., Science, 280:1371-1374 (1998)). However, the factors whichpredispose a fraction of patients to alteration of insulin secretion inresponse to fat accumulation remain unknown. The most common diseaseswith obesity are cardiovascular disease (particularly hypertension),diabetes (obesity aggravates the development of diabetes), gall bladderdisease (particularly cancer) and diseases of reproduction. Research hasshown that even a modest reduction in body weight can correspond to asignificant reduction in the risk of developing coronary heart disease.

Obesity considerably increases the risk of developing cardiovasculardiseases as well. Coronary insufficiency, atheromatous disease, andcardiac insufficiency are at the forefront of the cardiovascularcomplication induced by obesity. It is estimated that if the entirepopulation had an ideal weight, the risk of coronary insufficiency woulddecrease by 25% and the risk of cardiac insufficiency and of cerebralvascular accidents by 35%. The incidence of coronary diseases is doubledin subjects less than 50 years of age who are 30% overweight. Thediabetes patient faces a 30% reduced lifespan. After age 45, people withdiabetes are about three times more likely than people without diabetesto have significant heart disease and up to five times more likely tohave a stroke. These findings emphasize the inter-relations betweenrisks factors for NIDDM, obesity and coronary heart disease as well asthe potential value of an integrated approach involving the treatment ofboth obesity and diabetes (Perry, I. J. et al., BMJ, 310:560-564(1995)).

Type 2 diabetes results from the progressive loss of pancreatic β-cellfunction in the presence of insulin resistance, leading to an overallreduction in insulin output (Prentki, M. et al., “Islet failure in type2 diabetes”, J. Clin. Invest., 116:1802-1812 (2006)). β-cells are thecell type that store and release insulin in response to an elevation inplasma glucose or in response to hormonal signals from the gut followingthe ingestion of food. Evidence suggests that in type 2 diabetics therate of β-cell cell death (apoptosis) exceeds that of new β-celldevelopment, yielding an overall loss in β-cell number (Butler, A. E. etal., “(3-cell deficit and increased β-cell apoptosis in humans with type2 diabetes”, Diabetes, 52:102-110 (2003)). β-cell apoptosis may arisefrom persistent elevations in plasma glucose levels (glucotoxicity)and/or plasma lipid levels (lipotoxicity).

G-protein coupled receptors (GPCRs) expressed on β-cells are known tomodulate the release of insulin in response to changes in plasma glucoselevels (Ahren, B., “Autonomic regulation of islet hormonesecretion—Implications for health and disease”, Diabetologia, 43:393-410(2003)). Those GPCRs specifically coupled to the elevation of cAMP viathe G_(s) alpha subunit of G-protein, have been shown to enhanceglucose-stimulated insulin release from β-cells. Cyclic AMP-stimulatingGPCRs on β-cells include the GLP-1, GIP, β2-adrenergic receptors andGPR119. Increasing cAMP concentration in β-cells is known to lead to theactivation of PKA which is thought to prevent the opening of potassiumchannels on the surface of the β-cell. The reduction in K⁺ effluxdepolarizes the β-cell leading to an influx of Ca⁺⁺ which promotes therelease of insulin.

GPR119 (e.g., human GPR119, GenBank® Accession No. AAP72125 and allelesthereof; e.g., mouse GPR119, GenBank® Accession No. AY288423 and allelesthereof) is a GPCR located at chromosome position Xp26.1 (Fredricksson,R. et al., “Seven evolutionarily conserved human rhodopsin Gprotein-coupled receptors lacking close relatives”, FEBS Lett.,554:381-388 (2003)). The receptor is coupled to Gs, and when stimulated,produces an elevation in cAMP in a variety of cell types includingβ-cell-derived insulinomas (Soga, T. et al., “Lysophosphatidylcholineenhances glucose-dependent insulin secretion via an orphanG-protein-coupled receptor”, Biochem. Biophys. Res. Comm., 326:744-751(2005), International Applications WO 04/065380, WO 04/076413, WO05/007647, WO 05/007658, WO 05/121121, WO 06/083491, and EP 1338651).The receptor has been shown to be localized to the β-cells of thepancreas in a number of species as well as in specific cell types of thegastrointestinal tract. Activation of GPR119, with agonist ligands suchas lysophosphatidylcholine, produce a glucose dependent increase ininsulin secretion from primary mouse islets and various insulinoma celllines such as NIT-1 and HIT-T15 (Soga, T. et al.,“Lysophosphatidylcholine enhances glucose-dependent insulin secretionvia an orphan G-protein-coupled receptor”, Biochem. Biophys. Res. Comm.,326:744-751 (2005); Chu, Z. L. et al., “A role for (3-cell-expressedGPR119 in glycemic control by enhancing glucose-dependent insulinrelease”, Endocrinology, doi:10.1210/en.2006-1608 (2007)).

When activators of GPR119 are administered to either normal mice or micethat are prone to diabetes due to genetic mutation, prior to an oralglucose tolerance test, improvements in glucose tolerance are observed.A short-lived increase in plasma glucagon-like peptide-1 and plasmainsulin levels are also observed in these treated animals (Chu, Z. L. etal., “A role for β-cell-expressed GPR119 in glycemic control byenhancing glucose-dependent insulin release”, Endocrinology,doi:10.1210/en.2006-1608 (2007)). In addition to effects on plasmaglucose levels, GPR119 activators have also been demonstrated to producereductions in acute food intake and to reduce body weight in ratsfollowing chronic administration (Overton, H. A. et al.,“Deorphanization of a G protein-coupled receptor for oleoylethanolamideand its use in the discovery of small-molecule hypophagic agents”, CellMetabolism, 3:167-175 (2006), and patent applications WO 05/007647 andWO 05/007658).

SUMMARY OF THE INVENTION

In accordance with the present invention, a method for modulating theGPR119 G protein-coupled receptor is described as applied to thecompounds of Formula I and IA. In addition, a selected group ofcompounds are also disclosed for the same utility.

The method described herein is focused on the use of compounds ofFormula I and IA to modulate the GPR119 receptor, for example agonistsof the GPR119 receptor. Consequently, the compounds of the presentinvention may be used in the treatment of multiple diseases or disordersassociated with GPR119, such as diabetes and related conditions,microvascular complications associated with diabetes, the macrovascularcomplications associated with diabetes, cardiovascular diseases,Metabolic Syndrome and its component conditions, obesity and othermaladies. Examples of diseases or disorders associated with themodulation of the GPR119 G protein-coupled receptor that can beprevented, modulated, or treated according to the present inventioninclude, but are not limited to, diabetes, hyperglycemia, impairedglucose tolerance, insulin resistance, hyperinsulinemia, retinopathy,neuropathy, nephropathy, delayed wound healing, atherosclerosis and itssequelae, abnormal heart function, myocardial ischemia, stroke,Metabolic Syndrome, hypertension, obesity, dislipidemia, dyslipidemia,hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL,high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis,pancreatitis, neurodegenerative disease, lipid disorders, cognitiveimpairment and dementia, bone disease, HIV protease associatedlipodystrophy and glaucoma.

More particularly, the present invention relates to methods ofmodulating the activity of the GPR119 G protein-coupled receptorcomprising administering to a mammalian patient, for example, a humanpatient, in need thereof a therapeutically effective amount of acompound of the present invention, alone, or optionally, in combinationwith another compound of the present invention and/or at least one othertype of therapeutic agent.

Even more particularly, the present invention relates to a method forpreventing, modulating, or treating the progression or onset of diseasesor disorders associated with the activity of the GPR119 Gprotein-coupled receptor comprising administering to a mammalianpatient, for example, a human patient, in need of prevention,modulation, or treatment a therapeutically effective amount of acompound of the present invention, alone, or, optionally, in combinationwith another compound of the present invention and/or at least one othertype of therapeutic agent.

Examples of diseases or disorders associated with the activity of theGPR119 G protein-coupled receptor that can be prevented, modulated, ortreated according to the present invention include, but are not limitedto, diabetes, hyperglycemia, impaired glucose tolerance, insulinresistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy,delayed wound healing, atherosclerosis and its sequelae, abnormal heartfunction, myocardial ischemia, stroke, Metabolic Syndrome, hypertension,obesity, dislipidemia, dyslipidemia, hyperlipidemia,hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL,non-cardiac ischemia, infection, cancer, vascular restenosis,pancreatitis, neurodegenerative disease, lipid disorders, cognitiveimpairment and dementia, bone disease, HIV protease associatedlipodystrophy and glaucoma.

The present invention relates to a method for preventing, modulating, ortreating the progression or onset of diabetes, hyperglycemia, obesity,dyslipidemia, hypertension and cognitive impairment comprisingadministering to a mammalian patient, for example, a human patient, inneed of prevention, modulation, or treatment a therapeutically effectiveamount of a compound of the present invention, alone, or, optionally, incombination with another compound of the present invention and/or atleast one other type of therapeutic agent.

The present invention relates to a method for preventing, modulating, ortreating the progression or onset of diabetes, comprising administeringto a mammalian patient, for example, a human patient, in need ofprevention, modulation, or treatment a therapeutically effective amountof a compound of the present invention, alone, or, optionally, incombination with another compound of the present invention and/or atleast one other type of therapeutic agent.

The present invention relates to a method for preventing, modulating, ortreating the progression or onset of hyperglycemia comprisingadministering to a mammalian patient, for example, a human patient, inneed of prevention, modulation, or treatment a therapeutically effectiveamount of a compound of the present invention, alone, or, optionally, incombination with another compound of the present invention and/or atleast one other type of therapeutic agent.

The present invention relates to a method for preventing, modulating, ortreating the progression or onset of obesity comprising administering toa mammalian patient, for example, a human patient, in need ofprevention, modulation, or treatment a therapeutically effective amountof a compound of the present invention, alone, or, optionally, incombination with another compound of the present invention and/or atleast one other type of therapeutic agent.

For example, the present invention relates to a method for preventing,modulating, or treating the progression or onset of dyslipidemiacomprising administering to a mammalian patient, for example, a humanpatient, in need of prevention, modulation, or treatment atherapeutically effective amount of a compound of the present invention,alone, or, optionally, in combination with another compound of thepresent invention and/or at least one other type of therapeutic agent.

In another example, the present invention relates to a method forpreventing, modulating, or treating the progression or onset ofhypertension comprising administering to a mammalian patient, forexample, a human patient, in need of prevention, modulation, ortreatment a therapeutically effective amount of a compound of thepresent invention, alone, or, optionally, in combination with anothercompound of the present invention and/or at least one other type oftherapeutic agent.

In a special combination, the present invention relates to the use of aformulated product wherein the selected formulation is made by combining(a) a compound of Formula I and/or IA (using any of the compoundembodiments listed herein) and (b) a dipeptidyl peptidase-IV (DPP4)inhibitor.

The compounds of Formula I and IA can be administered for any of theuses described herein by any suitable means, for example, orally, suchas in the form of tablets, capsules, granules or powders; sublingually;bucally; parenterally, such as by subcutaneous, intravenous,intramuscular, or intrasternal injection, or infusion techniques (e.g.,as sterile injectable aqueous or non-aqueous solutions or suspensions);nasally, including administration to the nasal membranes, such as byinhalation spray; topically, such as in the form of a cream or ointment;or rectally such as in the form of suppositories; in dosage unitformulations containing non-toxic, pharmaceutically acceptable vehiclesor diluents.

In carrying out the method of the invention for treating diabetes andrelated diseases, a pharmaceutical composition will be employedcontaining the compounds of formula I, with or without otherantidiabetic agent(s) and/or antihyperlipidemic agent(s) and/or othertype therapeutic agents in association with a pharmaceutical vehicle ordiluent. The pharmaceutical composition can be formulated employingconventional solid or liquid vehicles or diluents and pharmaceuticaladditives of a type appropriate to the mode of desired administration,such as pharmaceutically acceptable carriers, excipients, binders, andthe like. The compounds can be administered to a mammalian patient,including humans, monkeys, dogs, etc. by an oral route, for example, inthe form of tablets, capsules, beads, granules or powders. The dose foradults is preferably between 1 and 2,000 mg per day, which can beadministered in a single dose or in the form of individual doses from1-4 times per day.

A typical capsule for oral administration contains one or more compoundsof Formula I or Formula IA (250 mg), lactose (75 mg), and magnesiumstearate (15 mg). The mixture is passed through a 60 mesh sieve andpacked into a No. 1 gelatin capsule.

A typical injectable preparation is produced by aseptically placing 250mg of one or more compounds of Formula I or Formula IA into a vial andthen aseptically freeze-drying and sealing. For use, the contents of thevial are mixed with 2 mL of physiological saline to produce aninjectable preparation.

The method of this invention comprises the administration of a compoundof Formula I or Formula IA or mixtures thereof:

wherein n₁, n₂, n₃, G, Q, X, R₁, R₂, R₂₀ and R₂₁ are defined below.

Compounds used in the method of the present invention modulate theactivity of G protein-coupled receptors. Preferably, compounds of thepresent invention modulate the activity of the GPR119 G protein-coupledreceptor (“GPR119”). Consequently, the compounds of the presentinvention may be used in the treatment of multiple diseases or disordersassociated with GPR119, such as diabetes and related conditions,microvascular complications associated with diabetes, the macrovascularcomplications associated with diabetes, cardiovascular diseases,Metabolic Syndrome and its component conditions, obesity and othermaladies. Examples of diseases or disorders associated with themodulation of the GPR119 G protein-coupled receptor that can beprevented, modulated, or treated according to the present inventioninclude, but are not limited to, diabetes, hyperglycemia, impairedglucose tolerance, insulin resistance, hyperinsulinemia, retinopathy,neuropathy, nephropathy, delayed wound healing, atherosclerosis and itssequelae, abnormal heart function, myocardial ischemia, stroke,Metabolic Syndrome, hypertension, obesity, dislipidemia, dyslipidemia,hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL,high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis,pancreatitis, neurodegenerative disease, lipid disorders, cognitiveimpairment and dementia, bone disease, HIV protease associatedlipodystrophy and glaucoma.

In addition, the present invention relates to a formulated productwherein the selected formulation is made by using a compound of FormulaI and/or IA as the only active ingredient or by combining (a) a compoundof Formula I and/or IA (using any of the compound embodiments listedherein) and (b) an additional active ingredient, for example, dipeptidylpeptidase-IV (DPP4) inhibitor (for example, a member selected fromsaxagliptin, sitagliptin, vildagliptin and alogliptin).

The present invention provides for compounds of Formula I and IA,pharmaceutical compositions employing such compounds, and for methods ofusing such compounds. In particular, the present invention provides apharmaceutical composition comprising a therapeutically effective amountof a compound of Formula I and/or IA, alone or in combination with apharmaceutically acceptable carrier.

Further, in accordance with the present invention, a method is providedfor preventing, modulating, or treating the progression or onset ofdiseases or disorders associated with the activity of the GPR119 Gprotein-coupled receptor, such as defined above and hereinafter, whereina therapeutically effective amount of a compound of formula I isadministered to a mammalian, i.e., human, patient in need of treatment.

The compounds of the invention can be used alone, in combination withother compounds of the present invention, or in combination with one ormore other agent(s).

Further, the present invention provides a method for preventing,modulating, or treating the diseases as defined above and hereinafter,wherein a therapeutically effective amount of a combination of acompound of Formula I and/or IA and another compound of Formula I or IAand/or at least one other type of therapeutic agent, is administered toa mammalian, i.e., human, patient in need of treatment.

DESCRIPTION OF THE INVENTION

A method of modulating the activity of the GPR119 G protein-coupledreceptor comprising administering to a mammalian patient in need thereofa therapeutically effective amount of at least one compound of Formula Ior Formula IA and, optionally, an additional therapeutic agent whereinthe compound of Formula I or Formula IA is selected from:

including enantiomers, diastereomers, solvates and salts thereof(particularly enantiomers, diastereomers and pharmaceutically acceptablesalts thereof) having ring A and ring B, wherein:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein theheteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachcontain 1-4 heteroatoms selected from N, O and S;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a),and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyleach contain 1-4 heteroatoms selected from N, O and S;

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,

—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a),and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyleach contain 1-4 heteroatoms selected from N, O and S;

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

The terms “Formula I” and “Formula IA” and all embodiments thereof shallinclude enantiomers, diastereomers, solvates and salts thereof(particularly enantiomers, diastereomers and pharmaceutically acceptablesalts thereof).

In a second embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl or a 6-membered monocyclicheteroaryl, each of which may be optionally substituted with one or moremembers selected from R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;

—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a third embodiment, a method of modulating the activity of the GPR119G protein-coupled receptor wherein for the compound of Formula I orFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is phenyl, pyridinyl, pyrazinyl or pyrimindinyl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a fourth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is phenyl or pyridinyl, each of which may be optionally substitutedwith one or more members selected from R_(1a), R_(1b), R_(1c), R_(1d)and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄; —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉;—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a fifth embodiment, a method of modulating the activity of the GPR119G protein-coupled receptor wherein for the compound of Formula I orFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is

each of which may be optionally substituted with one or more membersselected from the group consisting of R_(1a), R_(1b), R_(1c), R_(1d) andR_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein theheteroaryl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a sixth embodiment, a method of modulating the activity of the GPR119G protein-coupled receptor wherein for the compound of Formula I orFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄; —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a seventh embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCP₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCP₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)Rio and —OC(═O)R₁₀.

In an eighth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is aryl, heteroaryl, heterocyclyl, —C(═O)NR₃R₅, —C(═O)R₅ or—C(═O)OR₅, wherein the aryl, heteroaryl and heterocyclyl may each beoptionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄; —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a ninth embodiment a method of modulating the activity of the GPR119G protein-coupled receptor wherein for the compound of Formula I orFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is aryl, heteroaryl, or —C(═O)OR₅, wherein the aryland heteroaryl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a tenth embodiment, a method of modulating the activity of the GPR119G protein-coupled receptor wherein for the compound of Formula I orFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In an eleventh embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is heteroaryl which may be optionally substituted with one or moreR₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄; —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉;—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twelfth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is oxadiazolyl, benzoxazolyl, pyridinyl or pyrimidinyl, each of whichmay be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is pyrimidinyl which may be optionally substituted with one or moreR₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5 R₉₉;

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a fourteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is —C(═O)OR₅;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a fifteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is —C(═O)OR₅;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and

R₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a sixteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH or N, provided that Q and X are not both N;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a seventeenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C or N;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In an eighteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula Ior Formula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 1-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a nineteenth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twentieth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 0-2;

n₂ is 0-2;

n₃ is 2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄; —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉;—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-first embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 1;

n₂ is 1;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄;—S(O)₂NR₁₄C(═O)NR₁₄R₁₄; —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄; —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄;

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄; —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀;—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₀, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-second embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R_(iii), —S(O)₂R₁₀, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may each be optionally substituted with oneor more R₆'s; provided that at least one of R_(1a), R_(1b), R_(1c),R_(1d) and R_(1e) is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄,

—OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl;

R₁₀, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-third embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 1;

n₂ is 1;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-fourth embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-fifth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉, or S;

n₁ is 1;

n₂ is 1;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)Rio and —OC(═O)R₁₀.

In a twenty-sixth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroarylor a 6-membered monocyclic heteroaryl, each of which may be optionallysubstituted with one or more members selected from R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;

R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl or heterocyclylalkyl;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-seventh embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R_(iii), —S(O)₂R₁₀, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may each be optionally substituted with oneor more R₆'s; provided that at least one of R_(1a), R_(1b), R_(1c),R_(1d) and R_(1e) is heteroaryl;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5 R₉₉;

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-eighth embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,

—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a twenty-ninth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉, or S;

n₁ is 1;

n₂ is 1;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirtieth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉, or S;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-first embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl, and aryl, wherein the alkyl, cycloalkyl, and aryl may eachbe optionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl, and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)Rio and —OC(═O)R₁₀.

In a thirty-second embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is CH or N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-third embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl, and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-fourth embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O, OCR₉R₉ or S;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl, and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-fifth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl, and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-sixth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-5R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.

In a thirty-seventh embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula IA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a thirty-eighth embodiment, a method of modulating the activity ofthe GPR119 G protein-coupled receptor wherein for the compound ofFormula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is phenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e);

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R₈'s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a thirty-ninth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R₈; s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a fortieth embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl may be optionallysubstituted with one or more R₆'s;

R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, eachof which may be optionally substituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R₈; s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈, ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a forty-first embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of FormulaIA:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is pyridinyl, pyrimidinyl or —C(═O)OR₅, wherein the pyridinyl andpyrimidinyl may each be optionally substituted with one or more R₆'s;

R₅ is alkyl, aryl or cycloalkyl, each of which may be optionallysubstituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R₈; s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a forty-second embodiment, a method of modulating the activity of theGPR119 G protein-coupled receptor wherein for the compound of Formula I:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

n₃ is 2;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s;

R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s;

R₂ is pyridinyl, pyrimidinyl or —C(═O)OR₅, wherein the pyridinyl andpyrimidinyl may each be optionally substituted with one or more R₆'s;

R₅ is alkyl, aryl or cycloalkyl, each of which may be optionallysubstituted with one or more R₆'s;

R₆, at each occurrence, is independently selected from alkyl, haloalkyl,aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,

—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);

R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R₈; s;

R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄;

R₉, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each beoptionally substituted with 0-5 R_(9a);

R_(9a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O;

R₁₀, at each occurrence, is independently selected from alkyl,cycloalkyl and aryl, which may each be optionally substituted with 0-3R_(10a);

R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈;

R₁₄, at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl;

R₂₀ is hydrogen; and

R₂₁ is selected from the group consisting of hydrogen, alkyl, haloalkyl,halo and —CN.

In a forty-third embodiment, compounds of Formula IA are providedwherein:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, halo, CN and C₁₋₃ alkyl;

R_(1c) is imidazolyl, oxazolyl or triazolyl;

R₂ is pyrimidinyl or —C(═O)OR₅, wherein the pyrimidinyl may beoptionally substituted with C₁₋₃ alkyl;

R₅ is C₁₋₃ alkyl;

R₂₀ is hydrogen; and

R₂₁ is hydrogen, halo or CN.

One particular method uses the compounds of Formula I.

Another particular method uses the compounds of Formula IA (noting thatfor Formula IA there is no n₃ in the formula).

For each of the embodiments used in the invention and described in thisapplication, further and more particular values of the terms used ineach of the embodiments may be selected from the following definitions;these values may be used individually or in any combination in any ofthe embodiments. It is noted that for any occurrences of “═O”, these maybe used with suitable accommodation in the bond structure at that siteas will be appreciated by those skilled in the art.

The heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl usedin each occurrence may each contain 1-4 heteroatoms selected from N, Oand S.

R₁ may be selected from phenyl and a 6 membered monocyclic heteroarylhaving 1 or 2 N's wherein:

a) phenyl and heteroaryl may each be substituted with 1-3 membersselected from R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e);

b) R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selectedfrom the group consisting of hydrogen, C₁₋₃ alkyl, C₃₋₆ cycloalkyl,phenyl, halo, —CN, —OR₁₀, —OH, —SH, —SR₁₀, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀,—S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl,cycloalkyl and phenyl may each be optionally substituted with one ormore R₆'s; where R₆ may be selected from C₁₋₆ straight and branchedchain alkyl; C₃₋₆ cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; OH; phenyl;halo; C₁₋₆ haloalkyl; 5-6 membered heteroaryl having carbon atoms and1-2 heteroatoms selected from O, S and N; 5-6 membered heterocyclehaving carbon atoms and 1-2 heteroatoms selected from O and N; OCF₃;OR₁₀ where R₁₀ is C₁₋₃ alkyl or C₃₋₆ cycloalkyl; and SR₁₀ where R₁₀ isC₁₋₃ alkyl or C₃₋₆ cycloalkyl; and further wherein the alkyl, alkenyl,alkynyl, phenyl, cycloalkyl, heteroaryl and heterocyclyl values of R₆may each be optionally substituted with 0-3 R_(9a), where R_(9a) isselected from the group consisting of halo, C₁₋₃ haloalkyl, C₃₋₆cycloalkyl, OH, C₁₋₃ alkoxy, CN and ═O; and

c) R_(1c) is a 5 membered monocyclic heteroaryl having 1-3 heteroatomsselected from O and N, which may be optionally substituted with one ormore R₆'s; where R₆ may be selected from C₁₋₆ straight and branchedchain alkyl; C₃₋₆ cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; OH; phenyl;halo; C₁₋₆ haloalkyl; 5-6 membered heteroaryl having carbon atoms and1-2 heteroatoms selected from O, S and N; 5-6 membered heterocyclehaving carbon atoms and 1-2 heteroatoms selected from O and N; OCF₃;OR₁₀ where R₁₀ is C₁₋₃ alkyl or C₃₋₆ cycloalkyl; and SR₁₀ where R₁₀ isC₁₋₃ alkyl or

C₃₋₆ cycloalkyl; and further wherein the alkyl, alkenyl, alkynyl,phenyl, cycloalkyl, heteroaryl and heterocyclyl values of R₆ may each beoptionally substituted with 0-3 R_(9a), where R_(9a) is selected fromthe group consisting of halo, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃alkoxy, CN and ═O.

R₂ may be selected from —C(═O)OR₅, a 5-6 membered monocyclic heteroarylhaving 1-3 heteroatoms selected from O and N; and an 8-10 bicyclicheteroaryl having 1-3 heteroatoms selected from O and N, wherein:

i) the heteroaryls may be each be substituted with 1 or 2 of R₆, whereR₆ is selected from C₁₋₆ alkyl, C₁₋₃ haloalkyl, phenyl, C₃₋₆ cycloalkyl,halo, —CN, —OCF₃ and —OC₁₋₅alkyl, wherein the alkyl, phenyl, andcycloalkyl values for R₆ may each be optionally substituted with 0-2R_(9a) where R_(9a) is selected from halo, C₁₋₃ haloalkyl, C₃₋₆cycloalkyl, OH, C₁₋₃ alkoxy and CN; and

ii) R₅ is selected from the group consisting of C₁₋₆ straight andbranched chain alkyl, C₃₋₆ cycloalkyl and phenyl wherein the alkyl,phenyl, and cycloalkyl, may each be optionally substituted with 0-2 R₆wherein R₆ is as defined in i).

R₅ may be selected from the group consisting of C₁₋₆ straight andbranched chain alkyl, C₃₋₆ cycloalkyl and phenyl wherein:

i) the alkyl, phenyl, and cycloalkyl, may each be optionally substitutedwith 0-2 R₆;

ii) R₆ is selected from C₁₋₆ straight and branched chain alkyl; C₃₋₆cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; OH; phenyl; halo; C₁₋₆haloalkyl; 5-6 membered heteroaryl having carbon atoms and 1-2heteroatoms selected from O, S and N; 5-6 membered heterocycle havingcarbon atoms and 1-2 heteroatoms selected from O and N; OCF₃; ° R₁₀where R₁₀ is C₁₋₃ alkyl or C₃₋₆ cycloalkyl; and SR₁₀ where R₁₀ is C₁₋₃alkyl or C₃₋₆ cycloalkyl; and

iii) the alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, heteroaryl andheterocyclyl values of R₆ may each be optionally substituted with 0-3R_(9a), where R_(9a) is selected from the group consisting of halo, C₁₋₃haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃ alkoxy CN and ═O.

R₆ may be selected from C₁₋₆ straight and branched chain alkyl; C₃₋₆cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; OH; phenyl; halo; C₁₋₆haloalkyl; 5-6 membered heteroaryl having carbon atoms and 1-2heteroatoms selected from O, S and N; 5-6 membered heterocycle havingcarbon atoms and 1-2 heteroatoms selected from O and N; OCF₃; ° R₁₀where R₁₀ is C₁₋₃ alkyl or C₃₋₆ cycloalkyl; and SR₁₀ where R₁₀ is C₁₋₃alkyl or C₃₋₆ cycloalkyl; and further wherein the alkyl, alkenyl,alkynyl, phenyl, cycloalkyl, heteroaryl and heterocyclyl values of R₆may each be optionally substituted with 0-3 R_(9a), where R_(9a) isselected from the group consisting of halo, C₁₋₃ haloalkyl, C₃₋₆cycloalkyl, OH, C₁₋₃ alkoxy, CN and ═O.

R₈ is selected from the group consisting of C₁₋₆ straight and branchedchain alkyl and C₃₋₆ cycloalkyl each of which may be optionallysubstituted with one or more R_(sa)'s where R_(8a) is selected fromhalo, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃ alkoxy, CN and ═O.

R_(8a) is selected from halo, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃alkoxy, CN and ═O.

R₉ is selected from H, C₁₋₃ straight and branched chain alkyl and C₃₋₆cycloalkyl.

R_(9a) is selected from halo, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃alkoxy, CN and ═O.

R₁₀ is selected from C₁₋₃ straight and branched chain alkyl and C₃₋₆cycloalkyl.

R_(10a) is selected from halo, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, OH, C₁₋₃alkoxy, CN and ═O.

R₁₄ is H.

R₂₀ is H.

R₂₁ is selected from H, C₁₋₃ alkyl, C₃₋₆ cycloalkyl, halo and CN.

In a forty-fourth embodiment, compounds of the present invention areselected from the group of compounds exemplified in the Examples.

In a forty-fifth embodiment, the present invention relates to the use ofpharmaceutical compositions comprised of a therapeutically effectiveamount of a compound of Formula I or IA, alone or, optionally, incombination with a pharmaceutically acceptable carrier and/or one ormore other agent(s), for example, a glucagon-like peptide-1 receptoragonist or fragment thereof.

In a forty-sixth embodiment, the present invention relates to methods ofmodulating the activity of the GPR119 G protein-coupled receptorcomprising administering to a mammalian patient, for example, a humanpatient, in need thereof a therapeutically effective amount of acompound of the present invention, alone, or optionally, in combinationwith another compound of the present invention and/or at least one othertype of therapeutic agent.

In a forty-seventh embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofdiseases or disorders associated with the activity of the GPR119 Gprotein-coupled receptor comprising administering to a mammalianpatient, for example, a human patient, in need of prevention,modulation, or treatment a therapeutically effective amount of acompound of the present invention, alone, or, optionally, in combinationwith another compound of the present invention and/or at least one othertype of therapeutic agent.

Examples of diseases or disorders associated with the activity of theGPR119 G protein-coupled receptor that can be prevented, modulated, ortreated according to the present invention include, but are not limitedto, diabetes, hyperglycemia, impaired glucose tolerance, insulinresistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy,delayed wound healing, atherosclerosis and its sequelae, abnormal heartfunction, myocardial ischemia, stroke, Metabolic Syndrome, hypertension,obesity, dislipidemia, dyslipidemia, hyperlipidemia,hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL,non-cardiac ischemia, infection, cancer, vascular restenosis,pancreatitis, neurodegenerative disease, lipid disorders, cognitiveimpairment and dementia, bone disease, HIV protease associatedlipodystrophy and glaucoma.

In a forty-eighth embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofdiabetes, hyperglycemia, obesity, dyslipidemia, hypertension andcognitive impairment comprising administering to a mammalian patient,for example, a human patient, in need of prevention, modulation, ortreatment a therapeutically effective amount of a compound of thepresent invention, alone, or, optionally, in combination with anothercompound of the present invention and/or at least one other type oftherapeutic agent.

In a forty-ninth embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofdiabetes, comprising administering to a mammalian patient, for example,a human patient, in need of prevention, modulation, or treatment atherapeutically effective amount of a compound of the present invention,alone, or, optionally, in combination with another compound of thepresent invention and/or at least one other type of therapeutic agent.

In a fiftieth embodiment, the present invention relates to a method forpreventing, modulating, or treating the progression or onset ofhyperglycemia comprising administering to a mammalian patient, forexample, a human patient, in need of prevention, modulation, ortreatment a therapeutically effective amount of a compound of thepresent invention, alone, or, optionally, in combination with anothercompound of the present invention and/or at least one other type oftherapeutic agent.

In a fifty-first embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofobesity comprising administering to a mammalian patient, for example, ahuman patient, in need of prevention, modulation, or treatment atherapeutically effective amount of a compound of the present invention,alone, or, optionally, in combination with another compound of thepresent invention and/or at least one other type of therapeutic agent.

In a fifty-second embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofdyslipidemia comprising administering to a mammalian patient, forexample, a human patient, in need of prevention, modulation, ortreatment a therapeutically effective amount of a compound of thepresent invention, alone, or, optionally, in combination with anothercompound of the present invention and/or at least one other type oftherapeutic agent.

In a fifty-third embodiment, the present invention relates to a methodfor preventing, modulating, or treating the progression or onset ofhypertension comprising administering to a mammalian patient, forexample, a human patient, in need of prevention, modulation, ortreatment a therapeutically effective amount of a compound of thepresent invention, alone, or, optionally, in combination with anothercompound of the present invention and/or at least one other type oftherapeutic agent.

In a fifty-fourth embodiment, the present invention relates to the useof a formulated product wherein the selected formulation is made bycombining (a) a compound of Formula I and/or IA. The compounds hereindescribed may have asymmetric centers. Compounds of the presentinvention containing an asymmetrically substituted atom may be isolatedin optically active or racemic forms. It is well known in the art how toprepare optically active forms, such as by resolution of racemic formsor by synthesis from optically active starting materials. Many geometricisomers of olefins, C═N double bonds, and the like can also be presentin the compounds described herein, and all such stable isomers arecontemplated in the present invention. Cis and trans geometric isomersof the compounds of the present invention are described and may beisolated as a mixture of isomers or as separated isomeric forms. Allchiral, diastereomeric, racemic forms and all geometric isomeric formsof a structure are intended, unless the specific stereochemistry orisomeric form is specifically indicated.

One enantiomer of a compound of Formula I and/or IA may display superioractivity compared with the other. Thus, all of the stereochemistries areconsidered to be a part of the present invention. When required,separation of the racemic material can be achieved by high performanceliquid chromatography (HPLC) using a chiral column or by a resolutionusing a resolving agent such as camphonic chloride as in Young, S. D. etal., Antimicrobial Agents and Chemotherapy, 2602-2605 (1995).

To the extent that compounds of Formula I and/or IA and salts thereof,may exist in their tautomeric form, all such tautomeric forms arecontemplated herein as part of the present invention.

The term “substituted”, as used herein, means that any one or morehydrogens on the designated atom or ring is replaced with a selectionfrom the indicated group, provided that the designated atom's or ringatom's normal valency is not exceeded, and that the substitution resultsin a stable compound. When a substituent is keto (i.e., ═O), then 2hydrogens on the atom are replaced.

When any variable (e.g., R₄) occurs more than one time in anyconstituent or formula for a compound, its definition at each occurrenceis independent of its definition at every other occurrence. Thus, forexample, if a group is shown to be substituted with (R₄)_(m) and m is0-3, then said group may optionally be substituted with up to three R₄groups and R₄ at each occurrence is selected independently from thedefinition of R₄. Also, combinations of substituents and/or variablesare permissible only if such combinations result in stable compounds.

When a bond to a substituent is shown to cross a bond connecting twoatoms in a ring, then such substituent may be bonded to any atom on thering. When a substituent is listed without indicating the atom via whichsuch substituent is bonded to the rest of the compound of a givenformula, then such substituent may be bonded via any atom in suchsubstituent. Combinations of substituents and/or variables arepermissible only if such combinations result in stable compounds.

As used herein, “alkyl” is intended to include both branched andstraight-chain saturated aliphatic hydrocarbon groups containing 1 to 20carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, inthe normal chain, such as methyl, ethyl, propyl, isopropyl, butyl,t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl,octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl, thevarious branched chain isomers thereof, and the like as well as suchgroups may optionally include 1 to 4 substituents such as halo, forexample F, Br, Cl, or I, or CF₃, alkyl, alkoxy, aryl, aryloxy,aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl,cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl,heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy,aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido,alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl,trihaloalkyl, and/or alkylthio.

Unless otherwise indicated, the term “alkenyl” as used herein by itselfor as part of another group refers to straight or branched chainradicals of 2 to 20 carbons, preferably 2 to 12 carbons, and morepreferably 2 to 8 carbons in the normal chain, which include one to sixdouble bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl,2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl,3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl,4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may beoptionally substituted with 1 to 4 substituents, namely, halogen,haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl,amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido,arylcarbonyl-amino, nitro, cyano, thiol, alkylthio, and/or any of thealkyl substituents set out herein.

Unless otherwise indicated, the term “alkynyl” as used herein by itselfor as part of another group refers to straight or branched chainradicals of 2 to 20 carbons, preferably 2 to 12 carbons and morepreferably 2 to 8 carbons in the normal chain, which include one triplebond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl,4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl,4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl,and the like, and which may be optionally substituted with 1 to 4substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl,alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl,cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino,nitro, cyano, thiol, and/or alkylthio, and/or any of the alkylsubstituents set out herein.

Unless otherwise indicated, the term “cycloalkyl” as employed hereinalone or as part of another group includes saturated or partiallyunsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groupscontaining 1 to 10 rings, preferably 1 to 3 rings, including monocyclicalkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl, containinga total of 3 to 20 carbons forming the ring, preferably 3 to 15 carbons,more preferably 3 to 10 carbons, forming the ring and which may be fusedto 1 or 2 aromatic rings as described for aryl, which includescyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclooctyl, cyclodecyl, cyclododecyl, cyclohexenyl,

any of which groups may be optionally substituted with 1 to 4substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy,arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl,arylcarbonylamino, amino, nitro, cyano, thiol, and/or alkylthio, and/orany of the substituents for alkyl.

Where alkyl groups as defined above have single bonds for attachment toother groups at two different carbon atoms, they are termed “alkylene”groups and may optionally be substituted as defined above for “alkyl”.

Where alkenyl groups as defined above and alkynyl groups as definedabove, respectively, have single bonds for attachment at two differentcarbon atoms, they are termed “alkenylene groups” and “alkynylenegroups”, respectively, and may optionally be substituted as definedabove for “alkenyl” and “alkynyl”.

“Halo” or “halogen” as used herein refers to fluoro, chloro, bromo, andiodo; and “haloalkyl” is intended to include both branched andstraight-chain saturated aliphatic hydrocarbon groups, for example CF₃,having the specified number of carbon atoms, substituted with 1 or morehalogen (for example —C_(v)F_(w) where v=1 to 3 and w=1 to (2v+1)).

Unless otherwise indicated, the term “aryl” as employed herein alone oras part of another group refers to monocyclic and bicyclic aromaticgroups containing 6 to 10 carbons in the ring portion (such as phenyl ornaphthyl, including 1-naphthyl and 2-naphthyl) and may optionallyinclude 1 to 3 additional rings fused to a carbocyclic ring or aheterocyclic ring (such as aryl, cycloalkyl, heteroaryl, orcycloheteroalkyl rings for example

and may be optionally substituted through available carbon atoms with 1,2, or 3 substituents, for example, hydrogen, halo, haloalkyl, alkyl,haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl,trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl,cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy,aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl,heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro,cyano, amino, substituted amino wherein the amino includes 1 or 2substituents (which are alkyl, aryl, or any of the other aryl compoundsmentioned in the definitions), thiol, alkylthio, arylthio,heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl,arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl,aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino,arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino,or arylsulfonaminocarbonyl, and/or any of the alkyl substituents set outherein.

Unless otherwise indicated, the term “lower alkoxy”, “alkoxy”, “aryloxy”or “aralkoxy” as employed herein alone or as part of another groupincludes any of the above alkyl, aralkyl, or aryl groups linked to anoxygen atom.

Unless otherwise indicated, the term “amino” as employed herein alone oras part of another group refers to amino that may be substituted withone or two substituents, which may be the same or different, such asalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl,hydroxyalkyl, alkoxyalkyl, or thioalkyl. In addition, the aminosubstituents may be taken together with the nitrogen atom to which theyare attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl,4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl,4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl,1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy,alkylthio, halo, trifluoromethyl, or hydroxy.

Unless otherwise indicated, the term “lower alkylthio”, “alkylthio”,“arylthio” or “aralkylthio” as employed herein alone or as part ofanother group includes any of the above alkyl, aralkyl, or aryl groupslinked to a sulfur atom.

Unless otherwise indicated, the term “lower alkylamino”, “alkylamino”,“arylamino” or “arylalkylamino” as employed herein alone or as part ofanother group includes any of the above alkyl, aryl, or arylalkyl groupslinked to a nitrogen atom.

As used herein, the term “heterocyclyl” or “heterocyclic system” isintended to mean a stable 4- to 14-membered monocyclic, bicyclic ortricyclic heterocyclic ring which is saturated or partially unsaturatedand which consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, NH, O and S andincluding any bicyclic group in which any of the above-definedheterocyclic rings is fused to a benzene ring. The nitrogen and sulfurheteroatoms may optionally be oxidized. The heterocyclic ring may beattached to its pendant group at any heteroatom or carbon atom, whichresults in a stable structure. The heterocyclic rings described hereinmay be substituted on carbon or on a nitrogen atom if the resultingcompound is stable. If specifically noted, a nitrogen in the heterocyclemay optionally be quaternized. It is preferred that when the totalnumber of S and O atoms in the heterocycle exceeds 1, then theseheteroatoms are not adjacent to one another.

Examples of heterocycles include, but are not limited to, pyrrolidonyl,4-piperidonyl, chromanyl, decahydroquinolinyl,dihydrofuro[2,3-b]tetrahydrofuran, indolinyl, isochromanyl,isoindolinyloctahydroisoquinolinyl, piperazinyl, piperidinyl,piperidonyl, 4-piperidonyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,tetrahydroquinolinyl, morpholinyl, dihydrofuranyl, tetrahydrothiophenyl,pyranyl, dihydropyranyl, 1,4-dioxanyl and 1,3-dioxanyl. Also includedare fused ring and spiro compounds containing, for example, the aboveheterocycles.

As used herein, the term “aromatic heterocyclic system” or “heteroaryl”is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or7- to 10-membered bicyclic heterocyclic aromatic ring which consists ofcarbon atoms and from 1 to 4 heteroatoms independently selected from thegroup consisting of N, O and S and is aromatic in nature.

Examples of heteroaryls are 1H-indazole, 2H,6H-1,5,2-dithiazinyl,indolyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl,acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl,benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl,carbazolyl, 4aH-carbazolyl, β-carbolinyl, chromanyl, chromenyl,cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl,imidazolinyl, imidazolyl, indazolyl, indolenyl, indolinyl, indolizinyl,indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl,isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl,morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl,1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl,phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl,phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl,piperidinyl, pteridinyl, pteridinyl, purinyl, pyranyl, pyrazinyl,pyrazolidinyl, pyrazolinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl,pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl,pyrimidinyl, pyrrolidinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl,quinoxalinyl, quinuclidinyl, carbolinyl, 6H-1,2,5-thiadiazinyl,1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl,thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl,1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl,tetrazolyl, and xanthenyl. In another aspect of the invention, examplesof heteroaryls are indolyl, benzimidazolyl, benzofuranyl,benzothiofuranyl, benzoxazolyl, benzthiazolyl, benztriazolyl,benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl,cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinylisothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl,pyrazolotriazinyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl,pyrrolyl, quinazolinyl, quinolinyl, thiazolyl, thienyl, and tetrazolyl.

The term “heterocyclylalkyl” as used herein alone or as part of anothergroup refers to heterocyclyl groups as defined above linked through a Catom or heteroatom to an alkyl chain.

The term “heteroarylalkyl” or “heteroarylalkenyl” as used herein aloneor as part of another group refers to a heteroaryl group as definedabove linked through a C atom or heteroatom to an alkyl chain, alkylene,or alkenylene as defined above.

The term “cyano” as used herein, refers to a —CN group.

The term “nitro” as used herein, refers to an —NO₂ group.

The term “hydroxy” as used herein, refers to an OH group.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

As used herein, “pharmaceutically acceptable salts” refer to derivativesof the disclosed compounds wherein the parent compound is modified bymaking acid or base salts thereof. Examples of pharmaceuticallyacceptable salts include, but are not limited to, mineral or organicacid salts of basic residues such as amines; alkali or organic salts ofacidic residues such as carboxylic acids; and the like. Thepharmaceutically acceptable salts include the conventional non-toxicsalts or the quaternary ammonium salts of the parent compound formed,for example, from non-toxic inorganic or organic acids. For example,such conventional non-toxic salts include those derived from inorganicacids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric,nitric and the like; and the salts prepared from organic acids such asacetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric,citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic,benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric,toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic,and the like.

The pharmaceutically acceptable salts of the present invention can besynthesized from the parent compound which contains a basic or acidicmoiety by conventional chemical methods. Generally, such salts can beprepared by reacting the free acid or base forms of these compounds witha stoichiometric amount of the appropriate base or acid in water or inan organic solvent, or in a mixture of the two; generally, nonaqueousmedia like ether, ethyl acetate, ethanol, isopropanol, or acetonitrileare preferred. Lists of suitable salts are found in Remington'sPharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa.,p. 1418 (1985), the disclosure of which is hereby incorporated byreference.

Any compound that can be converted in vivo to provide the bioactiveagent (i.e., a compound of Formula I and/or IA) is a prodrug within thescope and spirit of the invention.

The term “prodrugs” as employed herein includes esters and carbonatesformed by reacting one or more hydroxyls of compounds of Formula Iand/or IA with alkyl, alkoxy, or aryl substituted acylating agentsemploying procedures known to those skilled in the art to generateacetates, pivalates, methylcarbonates, benzoates, and the like.

Various forms of prodrugs are well known in the art and are describedin:

a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch.31 (Academic Press, 1996);

b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985);

c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson andH. Bundgaard, eds. Ch. 5, pp. 113-191 (Harwood Academic Publishers,1991); and

d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and JoachimM. Mayer, (Wiley-VCH, 2003).

Said references are incorporated herein by reference, particularly as tothe description of prodrugs.

In addition, compounds of the Formula I and/or IA are, subsequent totheir preparation, preferably isolated and purified to obtain acomposition containing an amount by weight equal to or greater than 99%Formula I and/or IA compound (“substantially pure” compound I), which isthen used or formulated as described herein. Such “substantially pure”compounds of the Formula I and/or IA are also contemplated herein aspart of the present invention.

All stereoisomers of the compounds of the instant invention arecontemplated, either in admixture or in pure or substantially pure form.The compounds of the present invention can have asymmetric centers atany of the carbon atoms including any one of the R substituents and/orexhibit polymorphism. Consequently, compounds of Formula I and/or IA canexist in enantiomeric, or diastereomeric forms, or in mixtures thereof.The processes for preparation can utilize racemates, enantiomers, ordiastereomers as starting materials. When diastereomeric or enantiomericproducts are prepared, they can be separated by conventional methods forexample, chromatographic or fractional crystallization.

“Stable compound” and “stable structure” are meant to indicate acompound that is sufficiently robust to survive isolation to a usefuldegree of purity from a reaction mixture, and formulation into anefficacious therapeutic agent. The present invention is intended toembody stable compounds.

“Therapeutically effective amount” is intended to include an amount of acompound of the present invention alone or an amount of the combinationof compounds claimed or an amount of a compound of the present inventionin combination with other active ingredients effective to modulateGPR119 or effective to treat or prevent various disorders.

As used herein, “treating” or “treatment” cover the treatment of adisease-state in a mammal, particularly in a human, and include: (a)preventing the disease-state from occurring in a mammal, in particular,when such mammal is predisposed to the disease-state but has not yetbeen diagnosed as having it; (b) modulating the disease-state, i.e.,arresting it development; and/or (c) relieving the disease-state, i.e.,causing regression of the disease state.

Selected Compounds

In addition to the methods described above, this invention also includesselected compounds as described in the Examples and their utility forthe same purposes as recited for the method invention. These compoundsare selected from compounds of Formula IA and enantiomers, diastereomersand pharmaceutically acceptable salts thereof, wherein:

ring A is optionally substituted with one or more R's shown as R₂₀ andR₂₁;

G is N;

Q is C;

X is CH;

Y is O;

n₁ is 1;

n₂ is 1;

R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, halo, CN and C₁₋₃ alkyl;

R_(1c) is imidazolyl, oxazolyl or triazolyl;

R₂ is pyrimidinyl or —C(═O)OR₅, wherein the pyrimidinyl may beoptionally substituted with C₁₋₃ alkyl;

R₅ is C₁₋₃ alkyl;

R₂₀ is hydrogen; and

R₂₁ is hydrogen, halo or CN.

A more particular group of compounds are those described individually inthe Examples, especially Examples 1-4.

Synthesis

The compounds used in the methods of the present invention and theselected compounds recited in the Examples can be prepared in a numberof ways well known to one skilled in the art of organic synthesis. Thecompounds of the present invention can be synthesized using the methodsdescribed below, together with synthetic methods known in the art ofsynthetic organic chemistry, or variations thereon as appreciated bythose skilled in the art. Preferred methods include, but are not limitedto, those described below. All references cited herein are herebyincorporated in their entirety by reference.

The novel compounds of Formula I and/or IA may be prepared using thereactions and techniques described in this section. The reactions areperformed in solvents appropriate to the reagents and materials employedand are suitable for the transformations being effected. Also, in thedescription of the synthetic methods described below, it is to beunderstood that all proposed reaction conditions, including solvent,reaction atmosphere, reaction temperature, duration of the experimentand workup procedures, are chosen to be the conditions standard for thatreaction, which should be readily recognized by one skilled in the art.One skilled in the art of organic synthesis understands that thefunctionality present on various portions of the edict molecule must becompatible with the reagents and reactions proposed. Not all compoundsof Formula I and/or IA falling into a given class may be compatible withsome of the reaction conditions required in some of the methodsdescribed. Such restrictions to the substituents, which are compatiblewith the reaction conditions, will be readily apparent to one skilled inthe art and alternate methods must be used.

Compounds of Formula I and/or IA may be prepared by procedures depictedin Scheme 1. Intermediate 1, obtained from commercial sources, can bereacted with R₁X (where R₁ other than H is as defined with respect toFormula I and/or IA and X is a halide) in the presence of a ligand suchas 8-hydroxyquinoline, CuI (I) and a base such as K₂CO₃ in a suitablesolvent such as DMF, DMSO etc. at an elevated temperature to yieldintermediate 2. Cleavage of the benzyl group of intermediate 2 can beperformed using the methods known in the art such as hydrogenolysiscatalyzed by palladium. Intermediate 3 can then be alkylated withintermediate 4, which can be prepared by reaction of the correspondingalcohols with methanesulfonyl chloride, in the presence of a base suchas K₂CO₃ at an elevated temperature. The above alcohols are commerciallyavailable or can be prepared by many methods well known to one skilledin the art (typical examples may be found in Sandler, S. et al., OrganicFunctional Group Preparations, Vol. I (Academic Press, Inc., 1983)).Removal of the protecting group of intermediate 5 can be carried outwith appropriate reagents well known to those skilled in the art (forspecific details see Greene et al., Protecting Groups in OrganicSynthesis (John Wiley & Sons Inc., 1991)). The deprotected product canthen be treated with R₂X (where R₂ is defined as in Formula I and/or IAand X is a leaving group such as halide, mesylate, triflate, etc.),which are commercially available or can be prepared by many methodsknown in the art, at a number of conditions that are routine for thoseskilled in the art of organic synthesis to afford compounds of Formula Iand/or IA. Alternatively the intermediate 6 can also be reacted withisocyates or isothiocyanates in the presence of a base such as Et₃N toprovide the compounds of Formula I and/or IA.

Compounds of Formula I and/or IA, wherein Y is defined as S, S(═O) orS(O)₂, may be prepared by procedures outlined in Scheme 2. Halogenationof intermediate 3 generated as described in Scheme I can be achievedwith POBr₃, PBr₃ or POCl₃ using the conditions known to one skilled inthe art. The halogenated pyridone can then be reacted with intermediate8, which can be prepared according to the procedures described in U.S.Pat. No. 6,556,384 B1 (Owen, D et al.) incorporated by reference hereinas to these preparations, in the presence of a base such as NaH to yieldintermediate 9. Oxidation of intermediate 9 with an oxidant such asmCPBA in a suitable solvent such as CH₂Cl₂ affords intermediate 10 andintermediate 11. Intermediate 9, intermediate 10 or intermediate 11 canbe carried forward to compounds of Formula I and/or IA following theprocedures described above in Scheme 1 substituting intermediate 9, 10or 11 for intermediate 5.

Compounds of Formula I and/or IA, wherein Y is defined as NR₃, may beprepared by procedures illustrated in Scheme 3. Intermediate 7 preparedas described in Scheme II can be reacted with intermediate 12, which arecommercially available or can be prepared by the methods known to oneskilled in the art, in the presence of a catalyst such as Pd (P(tBu)₃)₂and a base such as NaOtBu in a suitable solvent such as toluene to yieldintermediate 13. The products can then be further elaborated tocompounds of Formula I and/or IA using the procedures described above inScheme 1 substituting intermediate 13 for intermediate 5.

Alternatively, compounds of Formula I and/or IA, wherein Y is defined asNR₃, may also be prepared by the procedures similar to those provided inScheme 3. Those invention compounds can be alternatively obtained bytreatment of the compounds of Formula I and/or IA, wherein R₃═H, with asuitable electrophile R₃X (where X is a halide, mesylate, triflate,etc.) in the presence of a base such as K₂CO₃, CsCO₃, NaOtBu, etc.

Alternatively, compounds of Formula I and/or IA can be synthesized byprocedures outlined in Scheme 4. Intermediate 14, obtained fromcommercial sources, can be reacted with intermediate 15, which arecommercially available or can be generated by many methods readilyrecognized by one skilled in the art (typical examples may be found inSandler, S. et al., Organic Functional Group Preparations, Vol. I(Academic Press, Inc., 1983)), in the presence of a base such as NaH toyield intermediate 16. Hydrolysis of intermediate 16 can be achieved bytreatment with DABCO in the presence of a base such as K₂CO₃ indioxane/water at an elevated temperature. Intermediate 17 can then bereacted with R₁X (where R₁ is defined with respect to Formula I and/orIA and X is a halide) in the presence of a ligand such as8-hydroxyquinoline, CuI (I) and a base such as K₂CO₃ in a suitablesolvent such as DMF, DMSO etc. at an elevated temperature to yieldintermediate 18. The intermediate 18 can be carried forward to compoundsof Formula I and/or IA following the procedures described above inScheme 1 substituting intermediate 18 for intermediate 5.

Compounds of Formula I and/or IA may be prepared by proceduresillustrated in Scheme 5. Intermediate 3 generated as described in SchemeI can be reacted with intermediate 19, which are commercially availableor can be made by many methods readily recognized by one skilled in theart (typical examples may be found in Sandler, S. et al., OrganicFunctional Group Preparations, Volume I, Academic Press, Inc., 1983),via Mitsunobo reaction to yield intermediate 20 which can be convertedto Formula I and/or IA using the procedures described above in Scheme 1substituting intermediate 20 for intermediate 5.

Alternatively, compounds of Formula I and/or IA may be synthesized asprovided in Scheme 6. Intermediate 21, obtained from commercial sources,can be reacted with intermediate 4 prepared as described in Scheme Itogive intermediate 22. Hydrolysis of intermediate 22 can be achieved bytreatment with DABCO in the presence of a base such as K₂CO₃ indioxane/water at an elevated temperature. Intermediate 23 can be treatedwith R₁X (where R₁ is defined with respect to Formula I and/or IA and Xis a halide) in the presence of a ligand such as 8-hydroxyquinoline, CuI(I) and a base such as K₂CO₃ in a suitable solvent such as DMF, DMSO etcat an elevated temperature to yield intermediate 24. The intermediate 24can be carried forward to compounds of Formula I and/or IA following theprocedures described above in Scheme 1 substituting intermediate 24 forintermediate 5.

Compounds of Formula I and/or IA can also be prepared by proceduresillustrated in Scheme 7. Intermediate 25 (R₁—NH₂, where R₁ is as definedin Formula I and/or IA), which are commercially available or can be madeby methods recognized by one skilled in the art, can be converted toformamidine intermediate 26 in a two step procedure described byDonetti, A. et al. (J. Med. Chem., 27:380 (1984)). Intermediate 26 canbe reacted with dimethyl malonate to yield intermediate 27 usingliterature procedures (J. Med. Chem., 45:3639 (2002)). The intermediate27 can then be carried forward to compounds of Formula I and/or IAfollowing the procedures described above in Scheme 1 substitutingintermediate 28 for intermediate 3.

Abbreviations

The following abbreviations are employed in the Examples and elsewhereherein:

EtOAc=ethyl acetateDMF=dimethylformamideTHF=tetrahydrofuranK₂CO₃=potassiumm carbonateNa₂CO₃=sodium carbonateMgSO₄=magnesium sulfateSiO₂=silicon dioxideCH₂Cl₂=methylene chlorideMeOH=methanolHCl=hydrochloric acidCs₂CO₃=cesium carbonateKOH=potassium hydroxideDME=1,2-dimethoxyethaneTFA=trifluoroacetic acidPd(dppf)Cl₂=[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II)t-BuONa=sodium tert-butoxidePd₂(dba)₃=tris(dibenzylideneacetone)dipalladium (0)BINAP=rac-2,2′-bis(diphenylphosphino)-1,1′-binaphthylmin=minute(s)h or hr=hour(s)mL or ml=milliliterg=gram(s)mg=milligram(s)mmol=millimole(s)LRMS=low resolution mass spectrometryNMR=nuclear magnetic resonance

EXAMPLES FOR SELECTED COMPOUNDS OF THE INVENTION

The following Examples are offered as illustrative as a partial scopeand as particular embodiments of the invention and are not meant to belimiting of the scope of the invention. Abbreviations and chemicalsymbols have their usual and customary meanings unless otherwiseindicated. Unless otherwise indicated, the compounds described hereinhave been prepared, isolated and characterized using the Schemes andother methods disclosed herein or may be prepared using same.

Example 1 Preparation of1-(4-(1H-1,2,4-triazol-1-yl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one,hydrochloride salt

Step A Preparation of 1-(5-propylpyrimidin-2-yl)piperidin-4-ol

To a stirring solution of piperidin-4-ol (2.33 g, 23.0 mmol, Aldrich)and potassium carbonate (6.36 g, 46.0 mmol, EMD) in DMF (15 mL) at roomtemperature was added 2-chloro-5-propylpyrimidine (4.33 g, 27.6 mmol,Wako). The reaction mixture was heated at 100° C. for 3 h then dilutedwith H₂O. The resulting mixture was extracted with EtOAc (2×). Theorganic layers were combined, dried over Na₂SO₄ and concentrated invacuo to a brown oil. The oil was purified by flash chromatography(SiO₂, 0 to 100% EtOAc in CH₂Cl₂) to yield 5.01 g of desired product asa white solid. MS (ESI) 222 (M+H).

Step B Preparation of 1-(5-propylpyrimidin-2-yl)piperidin-4-ylmethanesulfonate

To a stirring solution of 1-(5-propylpyrimidin-2-yl)piperidin-4-ol (9.2g, 41.6 mmol), Et₃N (12.85 mL, 91 mmol, Aldrich) in CH₂Cl₂ (80 mL) at 0°C. was added a solution of Methanesulfonyl chloride (3.54 mL, 45.7 mmol,Acros) in CH₂Cl₂ (20 mL) dropwise. The reaction mixture was stirred atroom temperature for 1 h and washed with 1N HCl in H₂O, saturated NaHCO₃in H₂O and brine. The organic layer was dried over Na₂SO₄ andconcentrated in vacuo to yield 11.7 g of the desired product as anoff-white solid. MS (ESI) 300 (M+H).

Step C Preparation of4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one

A stirring suspension of 4-hydroxypyridin-2(1H)-one (5.23 g, 47.1 mmol,Aldrich), 1-(5-propylpyrimidin-2-yl)piperidin-4-yl methanesulfonate(11.7 g, 39.2 mmol), potassium carbonate (12.5 g, 90.0 mmol, EMD) andDMSO (48 mL) was heated at 100° C. for 3 hours and then cooled to roomtemperature. The resulting mixture was diluted with H₂O and extractedwith EtOAc (2×). The organic layers were combined and concentrated invacuo to a brown solid. The solid was purified by flash chromatography(SiO₂, 100% EtOAc and then SiO₂, 10% MeOH in CH₂Cl₂) to yield 5.00 g ofdesired product as an off-white solid. MS (ESI) 315 (M+H).

Step D Preparation of 1-(4-bromophenyl)-1H-1,2,4-triazole

A mixture of 1H-1,2,4-triazole (122 mg, 1.78 mmol, Aldrich), K₃PO₄ (751mg, 3.53 mmol, Aldrich), Copper(I) iodide (33.7 mg, 0.177 mmol,Alfa-Aesar), 1-bromo-4-iodobenzene (500 mg, 1.78 mmol, Aldrich),(1S,2S)—N1,N2-dimethylcyclohexane-1,2-diamine (25 mg, 0.18 mmol, Strem)and DMSO (2 mL) was purged with Argon and then heated under microwavecondition at 140° C. for 30 min and then at 160° C. for 30 min. Thereaction mixture was diluted with H₂O and extracted with EtOAc (2×). Theorganic layers were combined and concentrated in vacuo to a brown oil.The solid was purified by flash chromatography (SiO₂, 0-100% EtOAc inhexanes) to yield 195 mg of desired product as a white solid. MS (ESI)224 (M+H).

Step E Preparation of1-(4-(1H-1,2,4-triazol-1-yl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one

A mixture of 1-(4-bromophenyl)-1H-1,2,4-triazole (45 mg, 0.20 mmol),4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one (58 mg,0.18 mmol), quinolin-8-ol (11 mg, 0.074 mmol, Alfa Aesar), potassiumcarbonate (33 mg, 0.24 mmol), Copper(I) iodide (14 mg, 0.074 mmol, AlfaAesar) in DMSO (2 mL) was heated under microwave condition at 160° C.for 30 min. The resulting mixture was diluted with H₂O and extractedwith EtOAc (2×). The combined organic layers were concentrated in vacuoto a green oil. The oil was purified by flash chromatography (SiO₂, 0 to100% EtOAc in CH₂Cl₂ and then SiO₂, 0 to 10% MeOH in CH₂Cl₂) to yield anoff-white solid. The solid was dissolved in DCM and 1 eq of HCl (1N HClin Et₂O) was added, the resulting mixture stirred for 5 min and thenconcentrated in vacuo to give 27 mg of desired product as an off-whitesolid. MS (ESI) 458 (M+H).

Step F Example 1

To a stirring solution of1-(4-(1H-1,2,4-triazol-1-yl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-onein CH₂Cl₂ was added 1 equivalent of HCl (1N HCl in Et₂O). This solutionwas stirred for 5 min and then concentrated in vacuo to give the desiredproduct as an off-white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.86 (br.s., 1H), 8.44 (s, 2H), 8.21 (br. s., 1H), 7.88 (d, J=8.28 Hz, 2H), 7.58(d, J=8.53 Hz, 2H), 7.35 (d, J=7.78 Hz, 1H), 6.20-6.34 (m, 1H), 6.15(dd, J=7.53, 2.01 Hz, 1H), 4.73-4.87 (m, 1H), 4.25-4.40 (m, 2H),4.10-4.25 (m, 2H), 2.56 (t, J=7.65 Hz, 2H), 2.10-2.22 (m, 4H), 1.61-1.72(m, 2H), 1.00 (t, J=7.40 Hz, 3H). MS (ESI) 458 (M+H).

Example 2 Preparation of1-(4-(1H-imidazol-1-yl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one,hydrochloride salt

Example B was prepared according to procedures described in Example 1substituting 1-(4-bromophenyl)-1H-imidazole (Oakwood) for1-(4-bromophenyl)-1H-1,2,4-triazole in Step E except that the crudesolid was purified by flash chromatography (SiO₂, 0 to 15% MeOH inCH₂Cl₂). The product was then converted to the hydrochloride salt byaddition of 1 equivalent of HCl (1N HCl in Et₂O) to the compoundstirring in CH₂Cl₂ for 5 min followed by concentration in vacuo to thedesired product. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.76 (br. s., 1H), 8.40(br. s., 2 H), 7.45-8.01 (m, 7H), 6.45-6.59 (m, 1H), 6.27-6.43 (m, 1H),4.87-5.18 (m, 1 H), 4.16-4.38 (m, 4H), 2.45-2.60 (m, 2H), 2.12-2.32 (m,2H), 1.94-2.11 (m, 2 H), 1.50-1.76 (m, 2H), 0.96 (t, J=7.15 Hz, 3H). MS(ESI) 457 (M+H).

Example 3 Preparation of1-(4-(oxazol-2-yl)phenyl)-4-(1-(5-propylpyrimidin-2-yl)piperidin-4-yloxy)pyridin-2(1H)-one

Example C was prepared according to procedures described in Example 1,Step A to E, substituting 2-(4-bromophenyl)oxazole (JW-Pharmlab) for1-(4-bromophenyl)-1H-1,2,4-triazole in Step E. ¹H NMR (400 MHz, CDCl₃) δppm 8.12-8.22 (m, 4H), 7.75 (s, 1H), 7.50 (d, J=8.53 Hz, 2H), 7.28 (br.s., 1H), 7.24-7.26 (m, 1H), 5.98-6.08 (m, 2H), 4.54-4.62 (m, 1H),4.16-4.26 (m, 2H), 3.58-3.70 (m, 2H), 2.42 (t, J=7.53 Hz, 2H), 2.03-2.18(m, 2H), 1.78-1.94 (m, 2H), 1.52-1.66 (m, 2H), 0.95 (t, J=7.28 Hz, 3H).MS (ESI) 458 (M+H).

Example 4 Preparation of isopropyl4-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate

Step A Preparation of isopropyl 4-hydroxypiperidine-1-carboxylate

To a stirring solution of piperidin-4-ol (5.22 g, 51.6 mmol, Aldrich),Et₃N (13.2 mL, 95 mmol, Aldrich) in CH₂Cl₂ (50 mL) at 0° C. was added asolution of Isopropyl chloroformate (1 Molar in Toluene, 43.0 mL, 43.0mmol, Aldrich) dropwise. The reaction mixture was stirred at roomtemperature for 1 h and washed with 1N HCl in H₂O. The H₂O layer wasextracted with DCM (2×). The organic layers were combined andconcentrated in vacuo to yield 5.71 g of the desired product as a lightbrown oil. MS (ESI) 188 (M+H).

Step B Example 4

Example 4 was prepared according to procedures described in Example 1,Step A to E substituting isopropyl 4-hydroxypiperidine-1-carboxylate for1-(5-propylpyrimidin-2-yl)piperidin-4-ol in Step B. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.62 (br. s., 1H), 8.16 (s, 1H), 7.79-7.88 (m, 2H),7.52-7.61 (m, 2H), 7.26-7.28 (m, 1H), 6.05 (dd, J=7.53, 2.76 Hz, 1H),6.00 (d, J=2.76 Hz, 1H), 4.90-5.01 (m, 1H), 4.48-4.56 (m, 1H), 3.72-3.84(m, 2H), 3.34-3.47 (m, 2H), 1.91-2.06 (m, 2 H), 1.76-1.91 (m, 2H), 1.28(d, J=6.27 Hz, 6H). MS (ESI) 424 (M+H).

Additional Examples

The following Examples are selected compounds that are believed to beparticularly active for modulating the GPR119 receptor and are a subsetof the compounds which may be prepared using the Schemes and methodsdescribed above, together with synthetic methods known in the art ofsynthetic organic chemistry, or variations thereon as appreciated bythose skilled in the art.

The compounds may be selected from any combinations of R_(1a), R_(1b),R_(1c), R_(1d), R_(1e), R₂₁ and R₂ shown in Table 1, Table 2 and Table 3to the extent that such compounds can be made stable as will beappreciated by those skilled in the art.

TABLE 1

R_(1a), R_(1b), R_(1d) or R_(1e) R_(1c) R₂₁ R₂ —H, —CH₃, —C₂H₅, —Cl, —F,—CN, —OCH₃, —OCF₃ or

—CH₃, —C₂H₅, —Cl, —Br, —F, —CN or

TABLE 2

R_(1a), R_(1b), R_(1d) or R_(1e) R_(1c) R₂₁ R₂ —H, —CH₃, —C₂H₅, —Cl, —F,—CN, OCH₃, —OCF₃ or

—CH₃, —C₂H₅, —Cl, —Br, —F, —CN or

TABLE 3

R_(1a), R_(1b), R_(1d) or R_(1e) R_(1c) R₂₁ R₂ —H, —CH₃, —C₂H₅, —Cl, —F,—CN, —OCH₃, —OCF₃ or

—CH₃, —C₂H₅, —Cl, —Br, —F, —CN or

Assay(s) for GPR119 G Protein-Coupled Receptor Activity

The in vitro modulation of recombinant human GPR119 was determined asfollows.

HIT-T15 cAMP Assay

A HIT-T15 hamster insulinoma cell line was purchased from ATCC and grownin the medium recommended by ATCC (i.e., Growth Medium: F12K Medium(Invitrogen 21127-022; 10% D-horse Serum; and 2.5% FBS).

To conduct the cAMP assay, cells expressing a GPR119 receptor are platedon 96 well plates (e.g., BD Falcon: REF 353948, black side, clearbottom, TC surface) at a density of about 4.5×10⁴ cells per well ingrowth medium and incubated overnight. Following incubation, the growthmedium is removed from the wells followed by a single rinse with theassay buffer from the Hit Hunter cAMP kit (100 μl/well). Following therinse, 20 μl of assay buffer is added to each well followed by additionof 10 μl of a 3× concentration of compound working solution. Thesolution is then mixed well. The final concentration range of compoundis from about 10⁻⁵M to about 10⁻¹¹M. The reaction is incubated at 37°C., in a 5% CO₂ for 1 hour. Following incubation, the cAMP concentrationis determined using the Hit Hunter cAMP kit according to themanufacturer's protocol.

Human Tet-Inducible cAMP Assay

Cell lines expressing GPR119 are generated using the Flp-In-T-REx 293tetracycline inducible gene expression system are cultured in culturemedium comprising the following components: DMEM#11965, 10% FBS, 2 mML-glutamine, 200 ug/ml Hygromycin B, and 15 ug/ml blasticidin.

For cAMP assays, cells are plated on 96 well plates (e.g., BD Falcon:REF 353948, black side, clear bottom, TC surface) at a density of about4.5×10⁴ cells per well in growth medium containing 1.0 ug/mltetracycline (1.0 mg/ml stock). The cells are then incubated for 48hours at 37° C.

Following the incubation, the growth medium is removed from the wellsand the wells rinsed (once) with the assay buffer included in the HitHunter cAMP kit (100 μl/well). Following the wash, 20 μl of assay bufferis added to each well, followed by addition of 10 μl of a 3×concentration compound working solution. The solution is then mixed. Thefinal concentration range of compound is from about 10⁻⁵M to about10⁻¹¹M. The reagents are then incubated at 37° C. at 5% CO₂ for 1 hour.

The manufacturer's protocol may be followed for cAMP determination. TheHit Hunter cAMP kit protocol is outlined for the HIT-T15 cAMP assaysdescribed above.

Compounds of the present invention were tested in the HumanTet-inducible cAMP assay described immediately above and the resultsshown in Table 4 below were obtained.

TABLE 4 Example hGPR119 EC₅₀ (nM) 1 87 2 94 3 204 4 5192

Luciferase Assay

HEK 293 cells may be plated on poly-D-lysine treated 96-well BD blackside/clear bottom plates at a density of about 3×10⁴ cells/well ingrowth medium. The growth medium may comprise the following: D-MEM (Cat#12430) with high glucose and 10% fetal bovine serum.

Cells may be transfected with vectors comprising native or non-nativeGPR119 sequences using commercially available vectors (e.g., Stratagene)and transfection reagents. The standard manufacturer's protocols may befollowed to transfect the cells. Following transfection, thetransfection medium may be removed and assay medium added to the wellsof the assay plates.

Once the assay plates are prepared, compound dilution plates may bemade. To do so, make a first compound dilution plate using 10 mM of thecompound of interest diluted to about 1 mM in DMSO. Then make 12 pointhalf-log dilutions of the compounds (in DMSO) using an automated liquidhandler. Next, make a second dilution plate by diluting the wells in thefirst plate ten fold (10×) using assay medium. Once the plates arecomplete, the highest dose is about 10 μM and the lowest dose is about0.03 nM.

Once the dilution plates are complete, one can add about 10 μl of the10× compound dilution to the assay plate containing the assay mediumtransiently transfected cells. Tap the plate to mix the reagents andincubate the plate overnight at 37° C., 95% O₂, and 5% CO₂ in anincubator.

Following incubation, a luciferase assay system may be used (e.g.,Stead-Glo Luciferase Assay System from Promega) according to themanufacturer's instructions. Following completion of the reaction,immediately measure the readout of the assay using a top countluminometer.

Mouse Oral Glucose Tolerance Test

24 male C57BL/6J mice (8-10 weeks old, average weight 28 g) wererandomized into 4 groups (1 mouse/cage) of 6 mice per group based on fedplasma glucose and body weight. Prior to initiating the study, mice werefasted overnight and the next morning they were weighed and placed inthe experimental lab. After 30 min in the environment, the mice werebled via tail tip at −30 min and immediately given their first oraladministration of vehicle (0.5% Methocel, 0.1% Tween 80 in water) orcompound solutions (5 ml/kg). At time 0 the mice were bled and given 50%glucose (2 g/kg) to initiate the oral glucose tolerance test (oGTT). Themice were bled 30, 60 and 120 min after the glucose load. Blood sampleswere drawn into potassium EDTA, placed on ice during the study andsubsequently centrifuged for 10 min at 3000 rpm at 4° C. Plasma sampleswere diluted 11-fold for glucose analysis in the Cobas Mira System(Roche Diagnostics). Area under the curve was calculated from the plasmaglucose time course data using the trapezoid rule with fasting plasmaglucose as the baseline (GraphPad Prism Software). The statisticalsignificance of the changes in the glucose AUCs resulting from thedifferent treatments was determined by one-way ANOVA followed byDunnett's test using the vehicle group as the control (JMP software,release 5.1.2).

Utilities and Combinations A. Utilities

The methods and compounds of the present invention possess activity asagonists of the GPR119 receptor, and, therefore, may be used in thetreatment of diseases associated with GPR119 receptor activity. Via theactivation of GPR119 receptor, the compounds of the present inventionmay preferably be employed to increase insulin production or increaseGLP-1 secretion or both.

Accordingly, the compounds of the present invention can be administeredto mammals, preferably humans, for the treatment of a variety ofconditions and disorders, including, but not limited to, treating,preventing, or slowing the progression of diabetes and relatedconditions, microvascular complications associated with diabetes,macrovascular complications associated with diabetes, cardiovasculardiseases, Metabolic Syndrome and its component conditions, inflammatorydiseases and other maladies. Consequently, it is believed that thecompounds of the present invention may be used in preventing,inhibiting, or treating diabetes, hyperglycemia, impaired glucosetolerance, insulin resistance, hyperinsulinemia, retinopathy,neuropathy, nephropathy, wound healing, atherosclerosis and its sequelae(acute coronary syndrome, myocardial infarction, angina pectoris,peripheral vascular disease, intermittent claudication, myocardialischemia, stroke, heart failure), Metabolic Syndrome, hypertension,obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia,hypercholesterolemia, low HDL, high LDL, vascular restenosis, peripheralarterial disease, lipid disorders, bone disease (includingosteoporosis), PCOS, HIV protease associated lipodystrophy, glaucoma andinflammatory diseases, such as, psoriasis, rheumatoid arthritis andosteoarthritis, and treatment of side-effects related to diabetes,lipodystrophy and osteoporosis from corticosteroid treatment.

Metabolic Syndrome or “Syndrome X” is described in Ford et al., J. Am.Med. Assoc., 287:356-359 (2002) and Arbeeny et al., Curr. Med.Chem.-Imm., Endoc. & Metab. Agents, 1:1-24 (2001).

B. Combinations

The present invention includes within its scope the use ofpharmaceutical compositions comprising, as an active ingredient, atherapeutically effective amount of at least one of the compounds ofFormula I and/or IA, alone or in combination with a pharmaceuticalcarrier or diluent. The present invention also includes within its scopethe use of pharmaceutical compositions comprising, as an activeingredient, a therapeutically effective amount of at least one of thecompounds of Formula I and/or IA, alone or in combination with apharmaceutical carrier or diluent. Optionally, compounds of the presentinvention can be used alone, in combination with other compounds of theinvention, or in combination with one or more other therapeuticagent(s), e.g., an antidiabetic agent or other pharmaceutically activematerial.

The methods of treatment using compounds of Formula I and/or IA of thepresent invention may be employed in combination with other GPR119receptor agonists or one or more other suitable therapeutic agentsuseful in the treatment of the aforementioned disorders including:anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemicagents, anti-retinopathic agents, anti-neuropathic agents,anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemicagents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemicagents, anti-dyslipidemic agents, anti-hyperlipidemic agents,anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents,anti-restenotic agents, anti-pancreatic agents, lipid lowering agents,appetite suppressants, treatments for heart failure, treatments forperipheral arterial disease and anti-inflammatory agents.

Examples of suitable anti-diabetic agents for use in combination withthe compounds of the present invention include insulin and insulinanalogs (e.g., LysPro insulin, inhaled formulations comprising insulin);glucagon-like peptides; sulfonylureas and analogs (e.g., chlorpropamide,glibenclamide, tolbutamide, tolazamide, acetohexamide, glypizide,glyburide, glimepiride, repaglinide, meglitinide); biguanides (e.g.,metformin, phenformin, buformin); alpha2-antagonists and imidazolines(e.g., midaglizole, isaglidole, deriglidole, idazoxan, efaroxan,fluparoxan); other insulin secretagogues (e.g., linogliride,insulinotropin, exendin-4,N,N-dimethyl-N′-[2-(4-morpholinyl)phenyl]guanidine (E)-2-butenedioatesalt (BTS-675820),(−)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166));thiazolidinediones and PPAR-gamma agonists (e.g., ciglitazone,pioglitazone, troglitazone, rosiglitazone); PPAR-alpha agonists e.g.,fenofibrate, gemfibrozil); PPAR alpha/gamma dual agonists (e.g.,muraglitazar, peliglitazar); SGLT2 inhibitors (e.g.,3-(benzo[b]furan-5-yl)-2′,6′-dihydroxy-4′-methylpropiophenone-2′-O-(6-O-methoxycarbonyl)-β-d-glucopyranoside(T-1095 Tanabe Seiyaku), phlorizin, TS-033 (Taisho), dapagliflozin(BMS), sergiflozin (Kissei), AVE 2268 (Sanofi-Aventis));11-beta-hydroxysteriod dehydrogenase type I inhibitors (e.g., AMG221,INCB13739); dipeptidyl peptidase-IV (DPP4) inhibitors (e.g.,saxagliptin, sitagliptin, vildagliptin, and denagliptin); glucagon-likepeptide-1 (GLP-1) receptor agonists (e.g., Exenatide (Byetta™), NN2211(Liraglutide, Novo Nordisk), AVE0010 (Sanofi-Aventis), R1583(Roche/Ipsen), SUN E7001 (Daiichi/Santory), GSK-716155 (GSK/Human GenomeSciences) and Exendin-4 (PC-DACTM); aldose reductase inhibitors (e.g.,those disclosed in WO 99/26659); RXR agonists (e.g., reglitazar(JTT-501),5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione(MCC-555),5-[[3-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-4-(trifluoromethoxy)phenyl]methylene]-2,4-thiazolidinedione(MX-6054), DRF2593, farglitazar,(±)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide(KRP-297),6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]-3-pyridinecarboxylicacid (LG100268)); fatty acid oxidation inhibitors (e.g., clomoxir,etomoxir; α-glucosidase inhibitors: precose, acarbose, miglitol,emiglitate, voglibose,2,6-dideoxy-2,6-imino-7-O-β-D-glucopyranosyl-D-glycero-L-gulo-heptitol(MDL-25,637), camiglibose); beta-agonists (e.g., methyl ester[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]-aceticacid (BRL 35135),2-[4-[(2S)-2-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]-aceticacid (BRL 37344),4-[(3R)-3-[bis[(2R)-2-hydroxy-2-phenylethyl]amino]butyl]-benzamide (Ro16-8714),2-[4-[2-[[(25)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)-acetamide(ICI D7114),5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-benzodioxole-2,2-dicarboxylicacid, disodium salt (CL 316,243), TAK-667, AZ40140); phosphodiesteraseinhibitors, both cAMP and cGMP type (e.g., sildenafil,9-((1S,2R)-2-fluoro-1-methylpropyl)-2-methoxy-6-(1-piperazinyl)purinehydrochloride (L-686398), L-386,398); amylin agonists (e.g.,pramlintide); lipoxygenase inhibitors (e.g., masoprocal); somatostatinanalogs (e.g., lanreotide, seglitide, octreotide); glucagon antagonists(e.g., BAY 276-9955); insulin signaling agonists, insulin mimetics,PTP1B inhibitors (e.g.,2-[2-(1,1-dimethyl-2-propenyl)-1H-indol-3-yl]-3,6-dihydroxy-5-[7-(3-methyl-2-butenyl)-1H-indol-3-yl]-2,5-cyclohexadiene-1,4-dione(L-783281), TER17411, TER17529); gluconeogenesis inhibitors (e.g.,GP3034); somatostatin analogs and antagonists; antilipolytic agents(e.g., nicotinic acid, acipimox, N-cyclohexyl-2′-O-methyl-adenosine (WAG994)); glucose transport stimulating agents (e.g.,4-chloro-α-[(4-methylphenyl)sulfonyl]-benzeneheptanoic acid(BM-130795)); glucose synthase kinase inhibitors (e.g., lithiumchloride, CT98014, CT98023); galanin receptor agonists; Chemokinereceptor antagonist CCR2/5 (e.g., NCB3284, MK-0812, INCB8696, maraviroc(Pfizer) and vicriviroc); thyroid receptor agonists (e.g., KB-2115(KaroBio)); Glucokinase activators (e.g., RO-27-4375, RO-28-1675(Roche),6-[[3-[(1S)-2-methoxy-1-methylethoxy]-5-[(1S)-1-methyl-2-phenylethoxy]benzoyl]amino]-3-pyridinecarboxylicacid (GKA-50 AstraZeneca)); GPR119 agonists (e.g., 1,1-dimethylethylester4-[[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]methoxy]-1-piperidinecarboxylicacid (PSN-632408 OSI Prosidion)); GDIR agonists (e.g., APD668 (Arena));GPR40 modulators (e.g.,(S)-4-(dimethylamino)-3-(4-((4-methyl-2-p-tolylthiazol-5-yl)methoxy)phenyl)-4-oxobutanoicacid,6-chloro-2-(4-chlorobenzylthio)-1-(4-(methoxymethoxy)phenyl)-1H-benzo[d]imidazole).

Examples of suitable lipid lowering agents and anti-atheroscleroticagents for use in combination with the compounds of the presentinvention include one or more MTP/ApoB secretion inhibitors (e.g.,dirlopatide,N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl-]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide,methanesulfonate, CP-741952 (Pfizer), SLx-4090 (Surface Logix)); HMG CoAreductase inhibitors (e.g., atorvastatin, rosuvastatin, simvastatin,pravastatin, lovastatin, fluvastatin); squalene synthetase inhibitors,PPAR alpha agonists and fibric acid derivatives (e.g., fenofibrate,gemfibrozil); ACAT inhibitors; lipoxygenase inhibitors; cholesterolabsorption inhibitors (e.g., ezetimibe); thyroid receptor agonists(e.g., as set forth above); Ileal Na+/bile acid cotransporter inhibitors(e.g., compounds as disclosed in Drugs of the Future, 24:425-430 (1999);upregulators of LDL receptor activity (e.g.,(3R)-3-[(13R)-13-hydroxy-10-oxotetradecyl]-5,7-dimethoxy-1(3H)-isobenzofuranone(Taisho Pharmaceutical Co. Ltd.) and(3α,4α,5α)-4-(2-propenyl)-cholestan-3-ol (Eli Lilly); bile acidsequestrants (e.g., WELCHOL®, COLESTID®, LOCHOLEST® and QUESTRAN®; andfibric acid derivatives, such as ATROMID®, LOPID® and TRICOT®);cholesterol ester transfer protein inhibitors (e.g., torcetrapib and(2R)-3-{[3-(4-chloro-3-ethyl-phenoxy)-phenyl]-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino}-1,1,1-trifluoro-2-propanol);nicotinic acid and derivatives thereof (e.g., niacin, acipimox); PCSK9inhibitors; LXR agonists (e.g., those disclosed in U.S. PatentApplication Publication Nos. 2003/01814206, 2005/0080111, and2005/0245515); lipoxygenase inhibitors (e.g., such as benzimidazolederivatives, as disclosed in WO 97/12615, 15-LO inhibitors, as disclosedin WO 97/12613, isothiazolones, as disclosed in WO 96/38144, and 15-LOinhibitors, as disclosed by Sendobry et al., “Attenuation ofdiet-induced atherosclerosis in rabbits with a highly selective15-lipoxygenase inhibitor lacking significant antioxidant properties”,Brit. J. Pharmacology, 120:1199-1206 (1997), and Cornicelli et al.,“15-Lipoxygenase and its Inhibition: A Novel Therapeutic Target forVascular Disease”, Current Pharmaceutical Design, 5:11-20 (1999)).

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin,atorvastatin, fluvastatin, cerivastatin, atavastatin, and rosuvastatin.

Examples of suitable anti-hypertensive agents for use in combinationwith the compounds of the present invention include beta adrenergicblockers, calcium channel blockers (L-type and T-type; e.g., diltiazem,verapamil, nifedipine, amlodipine and mybefradil), diuretics (e.g.,chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide,bendroflumethiazide, methylchlorothiazide, trichloromethiazide,polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone,furosemide, musolimine, bumetanide, triamtrenene, amiloride,spironolactone), renin inhibitors (e.g., aliskiren), ACE inhibitors(e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril,cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril), AT-1receptor antagonists (e.g., losartan, irbesartan, valsartan), ETreceptor antagonists (e.g., sitaxsentan, atrsentan, and compoundsdisclosed in U.S. Pat. Nos. 5,612,359 and 6,043,265), Dual ET/AIIantagonist (e.g., compounds disclosed in WO 00/01389), neutralendopeptidase (NEP) inhibitors, vasopeptidase inhibitors (dual NEP-ACEinhibitors) (e.g., omapatrilat and gemopatrilat), nitrates, centralalpha agonists (e.g., clonidine), alpha1 blockers (e.g., prazosine),arterial vasodilators (e.g., minoxidil), sympatolytics (e.g.,resperine), renin inhibitors (e.g., Aliskiren (Novartis)).

Examples of suitable anti-obesity agents for use in combination with thecompounds of the present invention include a cannabinoid receptor 1antagonist or inverse agonist (e.g., rimonabant,(4S)-3-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonyl]-4,5-dihydro-N′-methyl-4-phenyl-1H-pyrazole-1-carboximidamide(SLV 319), CP-945598 (Pfizer), Surinabant (SR-147778, Sanofi-Aventis),N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide(Merck) and those discussed in Hertzog, D. L., Expert Opin. Ther.Patents, 14:1435-1452 (2004)); a beta 3 adrenergic agonist (e.g.,rafabegron (AJ9677, Takeda/Dainippon),N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]phenyl]-4-(1-methylethyl)-benzenesulfonamide(L750355, Merck), or CP331648 (Pfizer), or other known beta 3 agonists,as disclosed in U.S. Pat. Nos. 5,541,204, 5,770,615, 5,491,134,5,776,983, and 5,488,064, with rafabegron,N-[4-[2-[[(2S)-3-[(6-amino-3-pyridinyl)oxy]-2-hydroxypropyl]amino]ethyl]phenyl]-4-(1-methylethyl)-benzenesulfonamide,and CP331648 being preferred); a lipase inhibitor (e.g., orlistat orcetilistat, with orlistat being preferred); a serotonin andnorepinephrine reuptake inhibitor (e.g., sibutramine, Abbott andtesofensine, Neurosearch) with sibutramine being preferred; a dopaminereuptake inhibitor (e.g., buproprion, GSK); or 5-HT_(2C) agonist, (e.g.,lorcaserin hydrochloride (Arena), WAY-163909[(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole],with lorcaserin hydrochloride being preferred); 5-HT6 receptorantagonists (Suven, Biovitrum, Epix), anti-epileptics topiramate(Johnson & Johnson) and zonisamide, a ciliary neurotrophic factoragonist (e.g., axokine (Regeneron); brain-derived neurotrophic factor(BDNF), orexin antagonists, histamine receptor-3 (H3) modulators,melanin-concentrating hormone receptor (MCHR) antagonists (e.g.,GSK-856464 (GlaxoSmithKline), T-0910792 (Amgen)); diacylglycerolacyltransferase (DGAT) inhibitors (e.g., BAY-74-4113 (Bayer));acetyl-CoA carboxylase (ACC) inhibitors (e.g.,N-(4-(4-(4-isopropoxyphenoxy)phenyl)but-3-yn-2-yl)acetamide (A-80040,Abbott),(R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-1,4′-bipiperidin-l′-yl)methanone(CP-640186, Pfizer)), SCD-1 inhibitors as described by Jiang et al.,Diabetes, 53 (2004), (abs 653-p); amylin receptor agonists (e.g.,compounds disclosed in WO 2005/025504); thyroid receptor agonists (e.g.,as set forth above); growth hormone secretagogue receptor (GHSR)antagonists (e.g., A-778193 (Abbott), leptin and leptin mimetics (e.g.,OB-3 (Aegis/Albany Medical College), leptin analogs A-100 and A-200(Amgen), CBT-001452 (Cambridge Biotechnology), ML-22952 (Millennium)),PYY receptor agonist (e.g., AC-162352 (Amylin), PYY-3-36 (Emishere),PYY(3-36)NH2 (Unigene)), NPY-Y4 agonists (7™ Pharma WO2005/089786(A2,A3)-1), NPY-5 antagonists (e.g., NPYSRA-972(AstraZeneca), GW-594884A (GlaxoSmithKline), J-104870 (Banyu)); MTP/apoBsecretion inhibitors (as set forth above), and/or an anorectic agent.

The anorectic agent which may be optionally employed in combination withcompounds of the present invention include dexamphetamine, phentermine,phenylpropanolamine, or mazindol, with dexamphetamine being preferred.

Other compounds that can be used in combination with the compounds ofthe present invention include CCK receptor agonists (e.g., SR-27895B);galanin receptor antagonists; MCR-4 antagonists (e.g.,N-acetyl-L-norleucyl-L-glutaminyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl-glycinamide,(HP-228); urocortin mimetics, CRF antagonists, and CRF binding proteins(e.g., mifepristone (RU-486), urocortin).

Further, the compounds of the present invention may be used incombination with HIV protease inhibitors, including but not limited toREYATAZ® and KALETRA®.

Examples of suitable memory enhancing agents, anti-dementia agents, orcognition promoting agents for use in combination with the compounds ofthe present invention include, but are not limited to aricept, razadyne,donepezil, rivastigmine, galantamine, memantine, tacrine, metrifonate,muscarine, xanomelline, deprenyl and physostigmine

Examples of suitable anti-inflammatory agents for use in combinationwith the compounds of the present invention include, but are not limitedto, NSAIDS, prednisone, acetaminophen, aspirin, codeine, fentanyl,ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin,piroxicam, sufentanyl, sunlindac, interferon alpha, prednisolone,methylprednisolone, dexamethazone, flucatisone, betamethasone,hydrocortisone, beclomethasone, remicade, orencia, and enbrel.

The aforementioned patents and patent applications are incorporatedherein by reference.

The above other therapeutic agents, when employed in combination withthe compounds of the present invention may be used, for example, inthose amounts indicated in the Physicians' Desk Reference, as in thepatents set out above, or as otherwise determined by one of ordinaryskill in the art.

1. A method of modulating activity of the GPR119 G protein-coupledreceptor comprising administering to a mammalian patient in need thereofa therapeutically effective amount of at least one compound of Formula Iand, optionally, an additional therapeutic agent wherein the compound ofFormula I is

and enantiomers, diastereomers and pharmaceutically acceptable saltsthereof having ring A and ring B, wherein: ring A is optionallysubstituted with one or more R's shown as R₂₀ and R₂₁; G is CH or N; Qis C or N; X is CH or N, provided that Q and X are not both N; Y is CH₂,N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2; n₂ is 0-2; n₃ is1-2; R₁ is a 6-membered monocyclic aryl, a 5-membered monocyclicheteroaryl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1c), R_(1d) andR_(1e) are each independently selected from the group consisting ofhydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionallysubstituted with one or more R₆'s; provided that at least one of R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e) is heteroaryl; R₂ is cycloalkyl, aryl,heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅, —C(═O)R₅ or —C(═O)OR₅,wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each beoptionally substituted with one or more R₆'s; R₃ is hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl or heterocyclylalkyl, wherein the heteroaryl,heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each contain 1-4heteroatoms selected from N, O and S; R₅ is alkyl, alkenyl, aryl,cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionallysubstituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a), and the heteroaryl,heteroarylalkyl, heterocyclyl and heterocyclylalkyl each contain 1-4heteroatoms selected from N, O and S; R_(9a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a),and the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyleach contain 1-4 heteroatoms selected from N, O and S; R_(10a), at eachoccurrence, is independently selected from alkyl, haloalkyl, aryl,alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃,—C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉, —S(O)₂NR₁₄C(═O)NR₁₄R₁₄,—C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄,—C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, at each occurrence, isindependently selected from hydrogen, alkyl, cycloalkyl and aryl; andR₂₀ and R₂₁ are each independently selected from the group consisting ofhydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.
 2. A methodaccording to claim 1 wherein: ring A is optionally substituted with oneor more R's shown as R₂₀ and R₂₁; G is CH or N; Q is C or N; X is CH orN, provided that Q and X are not both N; Y is CH₂, N(R₃), C(═O), O,OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2; n₂ is 0-2; n₃ is 1-2; R₁ isphenyl, pyridinyl, pyrazinyl or pyrimindinyl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1c), R_(1d) andR_(1e) are each independently selected from the group consisting ofhydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl,heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀,—OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionallysubstituted with one or more R₆'s; provided that at least one of R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e) is heteroaryl; R₂ is cycloalkyl, aryl,heteroaryl, heterocyclyl, —S(O)₂R₅, —C(═O)NR₃R₅, —C(═O)R₅ or —C(═O)OR₅,wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each beoptionally substituted with one or more R₆'s; R₃ is hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl or heterocyclylalkyl; R₅ is alkyl, alkenyl, aryl,cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionallysubstituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and R₂₀ and R₂₁ are each independently selectedfrom the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl,halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉,—C(═O)Rio and —OC(═O)R₁₀.
 3. A method according to claim 1 wherein: ringA is optionally substituted with one or more R's shown as R₂₀ and R₂₁; Gis CH or N; Q is C or N; X is CH or N, provided that Q and X are notboth N; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2;n₂ is 0-2; n₃ is 1-2; R₁ is each of which

may be optionally substituted with one or more members selected from thegroup consisting of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH,—C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl,—S(O)₂R₅, —C(═O)NR₃R₅, —C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl,aryl, heteroaryl and heterocyclyl may each be optionally substitutedwith one or more R₆'s; R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl orheterocyclylalkyl, wherein the heteroaryl; R₅ is alkyl, alkenyl, aryl,cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionallysubstituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄; —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; R₂₀ and R₂₁ are each independently selected fromthe group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, halo,—CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and—OC(═O)R₁₀.
 4. A method according to claim 1 wherein: ring A isoptionally substituted with one or more R's shown as R₂₀ and R₂₁; G isCH or N; Q is C or N; X is CH or N, provided that Q and X are not bothN; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2; n₂is 0-2; n₃ is 1-2; R₁ is a 6-membered monocyclic aryl, a 5-memberedmonocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each ofwhich may be optionally substituted with one or more members selectedfrom R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1c),R_(1d) and R_(1e) are each independently selected from the groupconsisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is aryl, heteroaryl, heterocyclyl, —C(═O)NR₃R₅,—C(═O)R₅ or —C(═O)OR₅, wherein the aryl, heteroaryl and heterocyclyl mayeach be optionally substituted with one or more R₆'s; R₃ is hydrogen,alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl or heterocyclylalkyl; R₅ is alkyl, alkenyl, aryl,cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionallysubstituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and R₂₀ and R₂₁ are each independently selectedfrom the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl,halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉,—C(═O)R₁₀ and —OC(═O)R₁₀.
 5. A method according to claim 1 wherein: ringA is optionally substituted with one or more R's shown as R₂₀ and R₂₁; Gis CH or N; Q is C or N; X is CH or N, provided that Q and X are notboth N; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2;n₂ is 0-2; n₃ is 1-2; R₁ is a 6-membered monocyclic aryl, a 5-memberedmonocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each ofwhich may be optionally substituted with one or more members selectedfrom R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1c),R_(1d) and R_(1e) are each independently selected from the groupconsisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroaryl maybe optionally substituted with one or more R₆'s; R₃ is hydrogen, alkyl,alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl or heterocyclylalkyl; R₅ is alkyl, alkenyl, aryl,cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionallysubstituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and R₂₀ and R₂₁ are each independently selectedfrom the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl,halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉,—C(═O)Rio and —OC(═O)Rio.
 6. A method according to claim 1 wherein: ringA is optionally substituted with one or more R's shown as R₂₀ and R₂₁; Gis CH or N; Q is C or N; X is CH or N, provided that Q and X are notboth N; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁ is 0-2;n₂ is 0-2; n₃ is 1-2; R₁ is a 6-membered monocyclic aryl, a 5-memberedmonocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each ofwhich may be optionally substituted with one or more members selectedfrom R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1c),R_(1d) and R_(1e) are each independently selected from the groupconsisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is heteroaryl which may be optionally substituted withone or more R₆'s; R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl orheterocyclylalkyl; R₆, at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀,—S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl,alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl may each be optionally substitutedwith 0-5 R_(9a); R₈, at each occurrence, is independently selected fromthe group consisting of alkyl, aryl, cycloalkyl, heteroaryl andheterocyclyl, each of which may be optionally substituted with one ormore R_(8a)'s; R_(8a), at each occurrence, is independently selectedfrom alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)OR₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; and R₂₀ and R₂₁ are each independently selectedfrom the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl,halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉,—C(═O)R₁₀ and —OC(═O)R₁₀.
 7. A method according to claim 1 wherein: ringA is optionally substituted with one or more R's shown as R₂₀ and R₂₁; Gis CH or N; Q is C or N; X is CH; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S,S(═O) or S(O)₂; n₁ is 0-2; n₂ is 0-2; n₃ is 1-2; R₁ is a 6-memberedmonocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-memberedmonocyclic heteroaryl, each of which may be optionally substituted withone or more members selected from R_(1a), R_(1b), R_(1c), R_(1d) andR_(1e); R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉,—S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀,—NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl,—S(O)₂R₅, —C(═O)NR₃R₅, —C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl,aryl, heteroaryl and heterocyclyl may each be optionally substitutedwith one or more R₆'s; R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl orheterocyclylalkyl; R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl orheterocyclyl, each of which may be optionally substituted with one ormore R₆'s; R₆, at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃,—C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a); R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄;—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄; —OCF₃, —OR₁₄; —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; R₂₀ is hydrogen; and R₂₁ is selected from the groupconsisting of hydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and—OC(═O)R₁₀.
 8. A method according to claim 1, wherein the compound isselected from compounds of Formula I in which: ring A is optionallysubstituted with one or more R's shown as R₂₀ and R₂₁; G is CH or N; Qis C; X is CH; Y is CH₂, N(R₃), C(═O), O, OCR₉R₉, S, S(═O) or S(O)₂; n₁is 0-2; n₂ is 0-2; n₃ is 2; R₁ is a 6-membered monocyclic aryl, a5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl,each of which may be optionally substituted with one or more membersselected from R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b),R_(1c), R_(1d) and R_(1e) are each independently selected from the groupconsisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,heteroaryl, heterocyclyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀,—OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉,—S(O)₂NR₉C(═O)NR₉R₉, —C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —C(═NR₁₄)NR₉R₉,—NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl andheterocyclyl may each be optionally substituted with one or more R₆'s;provided that at least one of R_(1a), R_(1b), R_(1c), R_(1d) and R_(1e)is heteroaryl; R₂ is cycloalkyl, aryl, heteroaryl, heterocyclyl,—S(O)₂R₅, —C(═O)NR₃R₅, —C(═O)R₅ or —C(═O)OR₅, wherein the cycloalkyl,aryl, heteroaryl and heterocyclyl may each be optionally substitutedwith one or more R₆'s; R₃ is hydrogen, alkyl, alkoxy, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl orheterocyclylalkyl; R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl orheterocyclyl, each of which may be optionally substituted with one ormore R₆'s; R₆, at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃,—C(═O)NR₉S(O)₂R₉, —S(O)₂NR₉C(═O)OR₉, —S(O)₂NR₉C(═O)NR₉R₉,—C(═O)NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—C(═NR₁₄)NR₉R₉, —NHC(═NR₁₄)NR₁₄R₁₄, —S(═O)R₁₀, —S(O)₂R₁₀, ═O,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl may each be optionally substituted with 0-5R_(9a); R₈, at each occurrence, is independently selected from the groupconsisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, eachof which may be optionally substituted with one or more R_(8a)'s;R_(8a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₄, —S(O)₂NR₁₄C(═O)OR₁₄,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, ═O, —NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at eachoccurrence, is independently selected from hydrogen, alkyl, alkoxy,cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyland heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃,—OR₁₄, —OH, —SH, —SR₁₄, —S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₁₀, —S(O)₂NR₁₄C(═O)OR₁₀,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈, ═O and arylalkyl;R₁₀, at each occurrence, is independently selected from alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-3 R_(10a);R_(10a), at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo,—NH₂, —CN, —NO₂, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —SH, —SR₁₄,—S(O)₃H, —P(O)₃H₂, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)NR₁₄S(O)₂R₉, —S(O)₂NR₁₄C(═O)OR₉,—S(O)₂NR₁₄C(═O)NR₁₄R₁₄, —C(═O)NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H,—NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —C(═NR₁₄)NR₁₄R₁₄, —NHC(═NR₁₄)NR₁₄R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and arylalkyl; R₁₄, ateach occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; R₂₀ is hydrogen; and R₂₁ is selected from the groupconsisting of hydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and—OC(═O)R₁₀.
 9. A method according to claim 1, wherein the compound isselected from compounds of Formula I in which: ring A is optionallysubstituted with one or more R's shown as R₂₀ and R₂₁; G is CH or N; Qis C; X is CH; Y is O, OCR₉R₉, or S; n₁ is 1; n₂ is 1; n₃ is 2; R₁ isphenyl or a 6-membered monocyclic heteroaryl, each of which may beoptionally substituted with one or more members selected from R_(1a),R_(1b), R_(1c), R_(1d) and R_(1e); R_(1a), R_(1b), R_(1d) and R_(1e) areeach independently selected from the group consisting of hydrogen,alkyl, alkenyl, alkynyl, cycloalkyl, halo, —CN, —OCF₃, —OR₁₀, —OH,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀,—NR₉C(═O)OR₈ and —NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl andcycloalkyl may each be optionally substituted with one or more R₆'s;R_(1c) is a 5-6 membered monocyclic heteroaryl which may be optionallysubstituted with one or more R₆'s; R₂ is heteroaryl or —C(═O)OR₅,wherein the heteroaryl may be optionally substituted with one or moreR₆'s; R₅ is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl orheterocyclyl, each of which may be optionally substituted with one ormore R₆'s; R₆, at each occurrence, is independently selected from alkyl,haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, —CN,—C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀,—OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R₈, at each occurrence, isindependently selected from the group consisting of alkyl, aryl,cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionallysubstituted with one or more R_(8a)'s; R_(8a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O,—NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at each occurrence, isindependently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl,heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may eachbe optionally substituted with 0-5 R_(9a); R_(9a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O; R₁₀, at each occurrence, isindependently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each beoptionally substituted with 0-3 R_(10a); R_(10a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈; R₁₄,at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; R₂₀ is hydrogen; and R₂₁ is selected from the groupconsisting of hydrogen, alkyl, haloalkyl, cycloalkyl, halo, —CN,—C(═O)OH, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and—OC(═O)R₁₀.
 10. A method according to claim 1, wherein the compound isselected from compounds of Formula I in which: ring A is optionallysubstituted with one or more R's shown as R₂₀ and R₂₁; G is N; Q is C; Xis CH; Y is O; n₁ is 1; n₂ is 1; n₃ is 2; R₁ is phenyl or a 6-memberedmonocyclic heteroaryl, each of which may be optionally substituted withone or more members selected from R_(1a), R_(1b), R_(1c), R_(1d) andR_(1e); R_(1a), R_(1b), R_(1d) and R_(1e) are each independentlyselected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,cycloalkyl, halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉,—S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀,—OC(═O)R₁₀, —OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl and cycloalkyl may eachbe optionally substituted with one or more R₆'s; R_(1c) is a 5-6membered monocyclic heteroaryl which may be optionally substituted withone or more R₆'s; R₂ is heteroaryl or —C(═O)OR₅, wherein the heteroarylmay be optionally substituted with one or more R₆'s; R₅ is alkyl,alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which maybe optionally substituted with one or more R₆'s; R₆, at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s; R_(8a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O,—NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at each occurrence, isindependently selected from hydrogen, alkyl, cycloalkyl and aryl, whichmay each be optionally substituted with 0-5 R_(9a); R_(9a), at eachoccurrence, is independently selected from alkyl, haloalkyl, aryl,alkenyl, alkynyl, cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄,—OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄,—NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄,—S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O; R₁₀, at eachoccurrence, is independently selected from alkyl, cycloalkyl and aryl,which may each be optionally substituted with 0-3 R_(10a); R_(10a), ateach occurrence, is independently selected from alkyl, haloalkyl, aryl,alkenyl, alkynyl, halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈; R₁₄, at each occurrence, isindependently selected from hydrogen, alkyl, cycloalkyl and aryl; R₂₀ ishydrogen; and R₂₁ is selected from the group consisting of hydrogen,alkyl, haloalkyl, cycloalkyl, halo, —CN, —C(═O)OH, —C(═O)OR₁₀, —OCF₃,—OR₁₀, —OH, —C(═O)NR₉R₉, —C(═O)R₁₀ and —OC(═O)R₁₀.
 11. A methodaccording to claim 1, wherein the compound is selected from compounds ofFormula I in which: ring A is optionally substituted with one or moreR's shown as R₂₀ and R₂₁; G is N; Q is C; X is CH; Y is O; n₁ is 1; n₂is 1; n₃ is 2; R₁ is

R_(1a), R_(1b), R_(1d) and R_(1e) are each independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,halo, —CN, —OCF₃, —OR₁₀, —OH, —C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉,—NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H, —NR₉C(═O)R₁₀, —OC(═O)R₁₀,—OC(═O)NR₉R₉, —S(═O)R₁₀, —S(O)₂R₁₀, —NR₉C(═O)OR₈ and —NR₉S(O₂)R₈,wherein the alkyl, alkenyl, alkynyl and cycloalkyl may each beoptionally substituted with one or more R₆'s; R_(1c) is a 5-6 memberedmonocyclic heteroaryl which may be optionally substituted with one ormore R₆'s; R₂ is pyridinyl, pyrimidinyl or —C(═O)OR₅, wherein thepyridinyl and pyrimidinyl may each be optionally substituted with one ormore R₆'s; R₅ is alkyl, aryl or cycloalkyl, each of which may beoptionally substituted with one or more R₆'s; R₆, at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,heterocyclylalkyl, halo, —CN, —C(═O)OR₁₀, —OCF₃, —OR₁₀, —OH, —SH, —SR₁₀,—C(═O)NR₉R₉, —NR₉R₉, —S(O)₂NR₉R₉, —NR₉S(O)₂CF₃, —C(═O)R₁₀, —NR₉C(═O)H,—NR₉C(═O)R₁₀, —OC(═O)R₁₀, —S(═O)R₁₀, —S(O)₂R₁₀, ═O, —NR₉C(═O)OR₈ and—NR₉S(O₂)R₈, wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl,cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl andheterocyclylalkyl may each be optionally substituted with 0-5 R_(9a);R₈, at each occurrence, is independently selected from the groupconsisting of alkyl and cycloalkyl, each of which may be optionallysubstituted with one or more R_(8a)'s; R_(8a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, ═O,—NR₁₄C(═O)OR₁₄ and —NR₁₄S(O₂)R₁₄; R₉, at each occurrence, isindependently selected from hydrogen, alkyl, cycloalkyl and aryl,wherein the alkyl, cycloalkyl and aryl may each be optionallysubstituted with 0-5 R_(9a); R_(9a), at each occurrence, isindependently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,cycloalkyl, halo, —NH₂, —CN, —C(═O)OH, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH,—C(═O)NR₁₄R₁₄, —NR₁₄R₁₄, —S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄,—NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄, —OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄,—NR₁₄C(═O)OR₈, —NR₁₄S(O₂)R₈ and ═O; R₁₀, at each occurrence, isindependently selected from alkyl, cycloalkyl and aryl, which may eachbe optionally substituted with 0-3 R_(10a); R_(10a), at each occurrence,is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl,halo, —NH₂, —CN, —C(═O)OR₁₄, —OCF₃, —OR₁₄, —OH, —C(═O)NR₁₄R₁₄, —NR₁₄R₁₄,—S(O)₂NR₁₄R₁₄, —NR₁₄S(O)₂CF₃, —C(═O)R₁₄, —NR₁₄C(═O)H, —NR₁₄C(═O)R₁₄,—OC(═O)R₁₄, —S(═O)R₁₄, —S(O)₂R₁₄, —NR₁₄C(═O)OR₈ and —NR₁₄S(O₂)R₈; R₁₄,at each occurrence, is independently selected from hydrogen, alkyl,cycloalkyl and aryl; R₂₀ is hydrogen; and R₂₁ is selected from the groupconsisting of hydrogen, alkyl, haloalkyl, halo and —CN.
 12. The methodof claim 1 comprising the use of an additional therapeutic agent. 13.The method of claim 12 wherein the additional therapeutic agent is adipeptidyl peptidase-IV (DPP4) inhibitor.